

## AUTHOR INDEX

- Aiken, R.D., 269, 348  
Armstrong, D.K., 681  
Atkins, M.B., 583
- Bain, S., 15  
Baselga, J., 369  
Belldgrun, A.S., 563, 607  
Benhadji, K.A., 466  
Berd, D., 708  
Berghorn, E.J., 15  
Better, N., 2  
Blute, M.L., 552  
Borges, L.F., 307  
Brown, R.J., 657  
Bruno, D., 696  
Bukowski, R.M., 596  
Byrd, J.C., 149, 157, 210  
Byrne, T.N., 307
- Caligaris-Cappio, F., 150  
Calin, G.A., 167  
Calvo, E., 421  
Calvo, F., 466  
Carter, C., 392  
Catovsky, D., 195  
Chan, K., 642  
Chang, C.C., 479  
Choueiri, T.K., 596  
Cordera, F., 631  
Crawford, J., 74  
Croce, C.M., 167  
Cullinan, S.B., 457  
Cvitkovic, E., 466
- Daly, M.B., 647  
Daniel, D., 74  
Darnell, R.B., 270  
Davidson, N.E., 657  
Davidson, R., 664  
de Jonge, M.J., 68  
DeAngelis, L.M., 324  
Dearden, C., 257  
Djelloul, S., 407  
Doll, D.C., 121  
Dragovich, T., 367  
Döhner, H., 186
- Ellis, M.J., 650
- Faivre, S., 407, 466  
Feeney, K.J., 629, 696  
Figlin, R.A., 525, 563, 607  
Floyd, J., 50, 98  
Fox, K., 664
- Ghia, P., 150  
Ghoul, A., 466  
Glass, J., 342  
Gollob, J.A., 392
- Goolsby, T.V., 139  
Gray, P.J., 367, 436  
Green, M.D., 2  
Grever, M.R., 210  
Gribben, J., 220
- Haider, S., 121  
Hamblin, T.J., 230  
Han, H., 513  
Hausheer, F.H., 15  
Houlston, R.S., 195  
Huang, Ru Chih C., 479  
Hurley, L.H., 498
- Jacobsohn, K.M., 576  
Jaecle, K.A., 312  
James, W.D., 86  
Johnson, M., 672  
Jordan, V.C., 631
- Kaelin Jr, W.G., 588  
Kay, N.E., 174  
Keating, M.J., 250  
Kelley, S.L., 392  
Kim, W.Y., 588  
Ko, J., 333  
Koh, M.Y., 486  
Krishnan, B., 257  
Kübler, H., 614  
Kumar Pal, S., 386  
Kuo, T., 299
- Lam, J.S., 563  
Le Dieu, R., 220  
Leibovich, B.C., 552  
Lieberman, F., 15  
Lin, T.S., 210  
Linehan, W.M., 544  
Lipworth, L., 527  
Loeffler, J.S., 307  
Lokiec, F., 466  
Lombardo, F.A., 139
- Ma, C.X., 650  
Matutes, E., 257  
McDermott, D.F., 583  
McLaughlin, J.K., 527  
Meadors, M., 98  
Mendelsohn, J., 369  
Mirza, I., 50  
Mitchell, E.P., 106  
Mold, D., 479  
Morris, G.J., 629, 642, 688  
Morrison, V.A., 240  
Mousses, S., 513
- Ng, R., 2
- O'Brien, S.M., 202
- Pandya, N., 688  
Pantuck, A.J., 607  
Papadopoulos, K., 449  
Park, M., 664  
Payne, A.S., 86  
Pegram, M., 386  
Perry, M.C., 50, 98  
Plass, C., 157  
Posner, J.B., 270  
Powis, G., 486  
Prehn, R.T., 708  
Prowell, T.M., 681  
Pruitt, A., 352
- Raval, A., 157  
Raymond, E., 407, 466  
Recht, L., 299  
Reuter, V.E., 534  
Rini, B.I., 596  
Rosenfeld, M.R., 352  
Rowinsky, E.K., 421
- Sachs, B., 50  
Schilsky, R.L., 15  
Seidman, A., 672  
Seiler, T., 186  
Sellick, G.S., 195  
Seroa, M., 466  
Shahab, N., 121  
Shanafelt, T.D., 174  
Shuch, B.M., 563  
Siddiqui-Jain, A., 498  
Sperling, M.R., 333  
Stilgenbauer, S., 186  
Sudarshan, S., 544  
Sul, J.K., 324
- Tarone, R.E., 527  
Thomas, G., 607  
Tsimberidou, A., 250
- Verweij, J., 68  
Vieweg, J., 614  
Von Hoff, D.D., 367, 436, 498, 513
- Wadhwa, P.D., 240  
Wang, H., 513  
Warner, S.L., 436  
Weiss, R.B., I, 86  
Welsh, S.J., 486  
Wheler, J., 672  
Whitesell, L., 457  
Wierda, W.G., 202  
Wilhelm, S., 392  
Wood, C.G., 576
- Yang, D., 498

## SUBJECT INDEX

- A30, *see* RNA aptamers  
 17AAG, *see* 17-Allylamino-17-demethoxygeldanamycin  
 Aberrant DNA methylation, in chronic lymphocytic leukemia, 162  
 Aberrant promoter hypermethylation, in chronic lymphocytic leukemia, 161-162  
 ABI-007, *see* Abraxane  
 Abraxane  
     clinical features of CIPN associated with, 27  
     for targeted cancer therapy, 424-425  
 ABT737, for Bcl-2 inhibition in targeted cancer therapy, 453  
 ACOSOG Z1031 Trial, 654-655  
 Adenoid cystic carcinoma, neurologic complications of, 349  
 Adhesion molecules, as prognostic marker of renal cell carcinoma, 572  
 Adrenal glands, and prognosis of renal cell carcinoma, 564  
 AEDs, *see* Anti-epileptic drugs  
 AG013736, for renal cell carcinoma, 602  
 Alemtuzumab, for chronic lymphocytic leukemia, 204  
     fludarabine-refractory, 212-213  
     relation to increased infection risk, 244-245  
 Alkylating agents  
     in cancer chemotherapy, neurotoxicity of  
         ifosfamide, 326-327  
         nitrosoureas, 327  
         platinum-based, 324-326  
     chemotherapy-related toxicity of  
         lung injury, 101-102  
         renal toxicity, 70-71  
     for chronic lymphocytic leukemia, 203  
         with purine analogue, 205-206  
         relation to increased infection risk, 242  
 Allogeneic stem cell transplantation, in chronic lymphocytic leukemia, risk  
     evaluation of, 192-193  
 All-trans retinoic acid, causing chemotherapy-related lung injury, 103  
 17-Allylamino-17-demethoxygeldanamycin, for targeted cancer therapy  
     as Hsp90 inhibitor, 459-462  
     as Raf kinase inhibitor, 399  
 Alternative nucleoside analogs, for fludarabine-refractory chronic lympho-  
     cytic leukemia, 214  
 Amifostine, for prevention and treatment of CIPN, 40-41  
 Analgesics, and renal cell carcinoma, 529-530  
 Androgen therapy, for prostate cancer, hormesis in, 708-709  
 Androgens, and anti-androgens, chemotherapy-related hepatotoxicity of, 59  
 Anemia, chemotherapy-related  
     cost analysis, 81  
     incidence, 78  
     quality of life, 79-81  
     treatment, 78-79  
     tumor response, 81-82  
 Angiogenesis  
     in chronic lymphocytic leukemia, 176-177  
         abnormal, therapeutic targeting, 180-181  
         prognostic implications, 179-180  
     Raf kinase isoforms as downstream effectors of, 397-398  
     role in cancer progression, 174-175  
 Angiogenesis inhibitors, for renal cell carcinoma  
     adjuvant therapy, 580  
     AG013736, 602  
 Angiogenesis inhibitors, for renal cell carcinoma (*Continued*)  
     anti-VEGF antibody, 596-599  
     BAY 43-9006, 601-602  
     controversies, 603-604  
     GW786034, 602-603  
     PTK 787/ZK222584, 602  
     SU11248, 599-601  
     VEGF-trap, 599  
 Angiogenic cytokines, biologic implications in chronic lymphocytic leuke-  
     mia, 178-179  
 Angiogenic factors  
     in hematopoietic cell development and hematologic malignancy, 175-176  
     serum/plasma levels in chronic lymphocytic leukemia, 176-177  
 Anthracyclines  
     cardiotoxicity of  
         dexrazoxane, 4-5  
         epirubicin, 4  
         liposomal doxorubicin formulations, 5  
         monitoring during treatment, 5-7  
         pediatric considerations, 3-4  
         prognosis and treatment, 10  
         scheduling, 4  
     for management of chemotherapy extravasation, 141-142  
 Anti-Bcl-2 agents, for targeted cancer therapy, 367, 449-456  
     antisense oligonucleotides, 450-451  
     miRNAs, 452  
     non-peptide antagonists, 452-453  
     peptide antagonists, 452  
 Anti-Bcl-xL agents, for targeted cancer therapy, 452  
 Antibodies  
     for fludarabine-refractory chronic lymphocytic leukemia, 216  
     intrathecal, for neoplastic meningitis, 320  
     in paraneoplastic encephalomyelitis, 280  
 Anticancer pharmacotherapy, *see* Chemotherapy  
 Antidepressants, for menopausal vasomotor symptoms in breast cancer sur-  
     vivors, 699  
 Anti-EGFR agents, for targeted cancer therapy, 367  
     clinical biomarker-driven studies, 376-377  
     implications for development, 375-376  
     integration with conventional therapies, 377-378  
     low-molecular-weight EGFR tyrosine kinase inhibitors, 373-375  
     mechanisms of action, 370-372  
     monoclonal antibodies, 372-373  
     optimal biological dose, 376  
     with other targeted therapies, 378-380  
     rational biomarker development, 376  
 Antiemetics, in cancer chemotherapy, neurotoxicity of, 330  
 Anti-epileptic drugs, for brain tumor patients  
     choice, effectiveness, and adverse reactions, 335-339  
     interactions with chemotherapy and glucocorticoids, 339  
     prophylactic use of, 334-335  
 Anti-estrogens  
     chemotherapy-related hepatotoxicity of, 59  
     for targeted cancer therapy, 472  
 Antigenic peptide vaccines, for renal cell carcinoma, 620  
 Antigen-presenting cells  
     artificial, and vaccines for renal cell carcinoma, 621

- Antigen-presenting cells (*Continued*)  
  role in pathogenesis of autoimmunity in chronic lymphocytic leukemia, 233
- Antigens, and b-cell chronic lymphocytic leukemia, 151-152
- Anti-HER2 agents, for targeted cancer therapy, 367, 386-391  
  monoclonal antibodies  
    pertuzumab, 389  
    trastuzumab, 388-389  
  peptidomimetics, 389-390  
  RNA aptamers, 390
- Antihormonal therapy, for breast cancer, 637  
  evolution of resistance to, 637-638
- Antihypertensive agents, and renal cell carcinoma, 529
- Anti-Mcl-1 agents, for targeted cancer therapy, 452
- Antimetabolites  
  in cancer chemotherapy, neurotoxicity of  
    cytarabine, 327-328  
    5-fluorouracil, 328  
    methotrexate, 327  
  chemotherapy-related toxicity of  
    dermatologic toxicity, 90-91  
    hepatotoxicity, 53-55  
    lung injury, 100-101  
    renal toxicity, 71-72
- Antimicrobial prophylaxis, in chronic lymphocytic leukemia, 246-247
- Anti-microtubule agents, for targeted cancer therapy, 367  
  discodermolide, 430  
  epothilones, 428-430  
  others, 430  
  taxanes, 422-423  
    abraxane, 424-425  
    advantages of, 423-424  
    CT-2103, 425-426  
    delivery systems, 424-428  
    DHA-paclitaxel, 426-427  
    emulsions, 427  
    oral bioavailability, 427-428
- Antimyosin antibody scintigraphy, in monitoring of anthracycline cardio-toxicity, 7
- Anti-PKC agents, for targeted cancer therapy  
  clinical trials, 473-474  
  combination with standard chemotherapy, 474  
  preclinical study  
    anti-estrogens, 472  
    antisense oligonucleotides, 473  
    bisindolmaleimides, 472-473  
    bryostatins, 471-473  
    calphostins, 473  
    ingenol derivatives, 473  
    phorbol 12-myristate 13-acetate, 471  
    staurosporine derivatives, 472
- Antisense oligonucleotides, for targeted cancer therapy  
  as Bcl-2 inhibitors, 450-451  
  as Bcl-xL inhibitors, 452  
  as Mcl-1 inhibitors, 452  
  as PKC modulators, 473  
  as Raf kinase inhibitors, 399
- Antitumor antibiotics, chemotherapy-related hepatotoxicity of, 55-56
- Anti-VEGF antibody, for renal cell carcinoma, 596-599  
  plus SU11248, 601
- Apoptosis  
  induced by *miR-15a* and *miR-16-1* genes, 171  
  role of PKC in, 469-470  
  survivin and, 479-480
- Aromatase inhibitors  
  in adjuvant therapy for postmenopausal women with breast cancer, 673  
  after 2 to years of tamoxifen, 674-676  
  clinical trials, 674  
  decision-making and future directions, 677-679
- Aromatase inhibitors (*Continued*)  
  extended adjuvant setting, 676-677  
  side effect profiles, 677  
  effects on bone loss, 689-691  
  effects on cognition, 693  
  effects on lipids, 691-692  
  effects on the musculoskeletal system, 692-693  
  principles of, 688-689  
  third-generation, in neoadjuvant endocrine therapy for locally advanced breast cancer, 651-652
- ARRY-142886, see Mitogen extracellular kinase inhibitors
- L-Asparaginase  
  in cancer chemotherapy, neurotoxicity of, 329  
  chemotherapy-related toxicity of  
    hepatotoxicity, 58  
    lung injury, 103
- Aurora kinases, as targets for cancer therapy, 367, 431  
  Aurora A, 437-439  
  Aurora B, 439-440
- Autoantibodies, produced by tumor cells in chronic lymphocytic leukemia, 231-232
- Autocrine VEGF pathway, in chronic lymphocytic leukemia, 177-178
- Autoimmunity, in chronic lymphocytic leukemia  
  clinical features, 231  
  pathogenesis  
    antigen-presenting cells, 233  
    role of T cells, 233  
    treatment-induced, 232-233  
    tumor cells in, 231-232  
  treatment  
    corticosteroids and cytotoxic drugs, 234  
    cyclosporine, 234  
    intravenous immunoglobulin, 234  
    others, 235  
    after purine analogues, 235-236  
    rituximab, 234-235  
    special factors, 235  
    splenectomy, 234
- Autologous stem cell transplantation, in chronic lymphocytic leukemia, risk evaluation of, 192-193
- Autonomic neuropathy, paraneoplastic, 279-280, 286-287
- Azacitidine, chemotherapy-related renal toxicity of, 71
- Azathioprine, chemotherapy-related hepatotoxicity of, 53-54
- BAY 43-9006, see Sorafenib
- B-cell chronic lymphocytic leukemia, origin of  
  dynamic properties of clone cells in, 153  
  immunoglobulin receptors in  
    antigen and progression, 152  
    antigenic element and, 151-152  
    circulating leukemia-like cells, 152-153  
  relevance of CD5 in, 153-154
- B-cell lymphoma 2-targeting agents, see Anti-Bcl-2 agents
- B-cell prolymphocytic leukemia  
  clinical features, 260  
  cytogenetics and pathogenesis, 260-261  
  differential diagnosis, 261  
  immunophenotype, 260  
  morphology, 260  
  treatment and prognosis, 261
- BCL2, post-translational inhibition of, and *miR-15a* and *miR-16-1* genes, 171
- bcl-2* gene, as prognostic marker of renal cell carcinoma, 572
- Bcl-2-targeting agents, see Anti-Bcl-2 agents
- Bcl-xL-targeting agents, see Anti-Bcl-xL agents
- Beta<sub>2</sub>-microglobulin, serum level as prognostic marker in chronic lymphocytic leukemia, 187
- Bevacizumab  
  chemotherapy-related toxicity of  
    hepatotoxicity, 57

- Bevacizumab (*Continued*)  
 lung injury, 102  
 for renal cell carcinoma, 596-599  
 plus SU11248, 601
- Bilateral diffuse uveal melanocytic proliferation, paraneoplastic, 284-285
- Biologic agents, intrathecal, for neoplastic meningitis, 320
- Biologic response modifiers, chemotherapy-related hepatotoxicity of, 58
- Biologic therapy, for fludarabine-refractory chronic lymphocytic leukemia, 216
- Biopsy  
 endomyocardial, in monitoring of anthracycline cardiotoxicity, 6  
 meningeal, in diagnosis of neoplastic meningitis, 314
- Birt-Hogg-Dubé syndrome, genetic basis of, 547-548
- Bisindolmaleimides, for targeted cancer therapy, 472-473
- Black cohosh, for menopausal vasomotor symptoms in breast cancer survivors, 698-699
- Bleomycin, chemotherapy-related toxicity of  
 hepatotoxicity, 56  
 lung injury, 98-99
- $\beta$ 2-MG, see Beta<sub>2</sub>-microglobulin
- BNP7787, see Tavocept
- Bone loss, effects of aromatase inhibitors on, 689-691
- Bone marrow, neovascularization in chronic lymphocytic leukemia, 176-177
- Bone marrow infiltration pattern, as marker of tumor burden in chronic lymphocytic leukemia, 186-187
- Bone marrow transplantation, in cancer, neurotoxicity of, 329  
 after marrow reconstitution, 355-356  
 chronic graft-versus-host disease and, 357  
 during conditioning, 353  
 long-term immunosuppression and, 356-357  
 during pancytopenia, 353-355  
 during stem cell harvesting, 353
- Bortezomib  
 in cancer chemotherapy, neurotoxicity of, 330  
 chemotherapy-related toxicity of  
 CIPN, clinical features of, 29  
 dermatologic toxicity, 93-94  
 hepatotoxicity, 58  
 lung injury, 103
- Brachial neuropathy, paraneoplastic, 288
- B-Raf, see Raf kinase isoforms
- Brain metastases  
 chemotherapy and other agents, 303-304  
 diagnosis, 299-300  
 pathophysiology, 299  
 patient classification according to prognosis, 300  
 prophylactic cranial irradiation, 304  
 radiation sensitizers, 304  
 stereotactic radiosurgery as alternative to resection, 301-302  
 symptomatic management, 300  
 treatment algorithm, 304-305  
 whole brain radiation therapy, 300, 302-303  
 resection and, 300-301
- Brain tumors, seizures in  
 AEDs for  
 choice, effectiveness, and adverse reactions, 335-339  
 interactions with chemotherapy and glucocorticoids, 339  
 prophylactic use of, 334-335  
 clinical features, 334  
 epidemiology, 333-334  
 surgical management, 339-340
- Brainstem encephalitis, paraneoplastic, 279
- Breast cancer  
 adjuvant hormonal therapy in premenopausal women  
 ovarian ablation and suppression, 658-660  
 recommendations from consensus meetings, 660  
 research directions, 660-662  
 tamoxifen, 657
- Breast cancer (*Continued*)  
 biology and growth of  
 antihormonal therapy, 637  
 coactivators and corepressors, 634  
 estrogen receptor activation, 638  
 estrogen receptor  $\alpha$  in, 633  
 estrogen receptor  $\beta$  in, 633-634  
 estrogen receptor in, 631-632  
 estrogen receptor signal transduction, 638  
 evolution of antihormone resistance, 637-638  
 gene activation by estrogen receptor, 634-635  
 HER growth factor receptors in, 636  
 heterogenous nature, 632  
 histone deacetylases and, 634  
 molecular mechanisms, 632-633  
 progesterone receptor in, 635-636  
 chemoprevention in high-risk women  
 benign lesions and genetic predisposition, 643-644  
 guidelines, 644-645  
 ongoing studies, 645  
 patient monitoring, 645  
 tamoxifen, 642-643  
 hormesis in estrogen therapy for, 709  
 hormonal therapy for, 629-630  
 role of Her-2/neu status, 681-686  
 locally advanced, neoadjuvant endocrine therapy for  
 ACOSOG Z1031 Trial, 654-655  
 biomarker analysis in, 653-654  
 as short-term surrogate to predict long-term outcomes, 653  
 tamoxifen, 650-651  
 third-generation aromatase inhibitors, 651-652  
 v chemotherapy, 652-653  
 in postmenopausal women  
 aromatase inhibitors for, 673-679  
 tamoxifen for, 672-673  
 in premenopausal women  
 fertility preservation and impact of subsequent pregnancy, 664-669  
 survivors, treatment of menopausal symptoms in, 696-704  
 cardiovascular disease, 703  
 osteoporosis, 700-702  
 urogenital atrophy, 702-703  
 vasomotor symptoms, 697-700  
 trastuzumab cardiotoxicity in adjuvant treatment of, 8-10
- Bronchospasm, chemotherapy-related, 98
- Bryostatins, for targeted cancer therapy, 471-472
- Budd-Chiari syndrome, chemotherapy-related, 124
- Busulfan, chemotherapy-related toxicity of  
 hepatotoxicity, 53  
 lung injury, 101
- Cachectic myopathy, paraneoplastic, 292
- Calcium/magnesium infusions, for acute oxaliplatin neuropathy, 42
- Calphostins, for targeted cancer therapy, 473
- Campt-1H, see Alemtuzumab
- Cancer  
 epigenetic deregulation in, 158-159  
 of kidney, see Kidney neoplasms  
 progression, role of angiogenesis, 174-175  
 targeted therapies for, 367-368, 408-409  
 anti-Bcl-2 agents, 449-456  
 antisense oligonucleotides, 450-451  
 miRNAs, 452  
 non-peptide antagonists, 452-453  
 peptide antagonists, 452  
 anti-EGFR agents  
 clinical biomarker-driven studies, 376-377  
 implications for development, 375-376  
 integration with conventional therapies, 377-378  
 low-molecular-weight EGFR tyrosine kinase inhibitors, 373-375

## Cancer (Continued)

- mechanisms of action, 370-372
- monoclonal antibodies, 372-373
- optimal biological dose, 376
- with other targeted therapies, 378-380
- rational biomarker development, 376
- anti-HER2 agents, 386-391
  - peptidomimetics, 389-390
  - pertuzumab, 389
  - RNA aptamers, 390
  - targeting multiple HER2 epitopes, 390-391
  - trastuzumab, 388-389
- anti-microtubule agents
  - abraxane, 424-425
  - CT-2103, 425-426
  - delivery systems, 424-428
  - DHA-paclitaxel, 426-427
  - discodermolide, 430
  - emulsions, 427
  - epothilones, 428-430
  - oral bioavailability, 427-428
  - others, 430
  - taxanes, 422-428
- anti-PKC agents
  - clinical trials, 473-474
  - combination with standard chemotherapy, 474
  - preclinical study, 470-473
- antisense Bcl-xL oligonucleotides, 452
- antisense Mcl-1 oligonucleotides, 452
- HIF-1 inhibitors, 491-493
- Hsp90 inhibitors, 457-462
  - clinical experience, 461-462
  - development, 459-461
- MtN as global transcription inhibitor, 483-484
- multitargeted, 407-417
  - investigational agents, 413-417
  - rationale, 409-411
  - strategies, 411-412
- Raf kinase inhibitors
  - 17AAG, 399
  - antisense oligonucleotides, 399
  - MEK inhibitors, 399
  - sorafenib tosylate, 399-403
- Cancer immunotherapy, hormesis in, 710
- Cancer-associated cone dysfunction, 284
- Candidiasis, gastrointestinal, chemotherapy-related, 114
- Capecitabine, chemotherapy-related dermatologic toxicity of, 90-91
- Capillary-leak syndrome, chemotherapy-related, 128
- Carbamazepine, for prevention and treatment of oxaliplatin-induced CIPN, 41-42
- Carbonic anhydrase IX, as prognostic marker of renal cell carcinoma, 570-571
- Carboplatin, chemotherapy-related toxicity of
  - CIPN, clinical features of, 24
  - v cisplatin, 27-28
  - renal toxicity, 70
- Carcinoma-in-situ, ductal, tamoxifen for, 647-649
- Cardiotoxicity
  - chemotherapy-related
    - anthracyclines, 2-7, 10
    - taxanes, 7-8
    - trastuzumab, 8-10
  - radiotherapy-related, 3
- Cardiovascular disease, menopausal, treatment among breast cancer survivors, 703
- Carmustine, causing chemotherapy-related lung injury, 101
- CD5, relevance in origin of b-cell chronic lymphocytic leukemia, 153-154
- CD23, soluble, serum level as prognostic marker in chronic lymphocytic leukemia, 187
- CD5<sup>+</sup> cells, miR-15a and miR-16-1 genes in, 168
- Cell division, and survivin, 480
- Cell survival, effects of Raf-1, 393-394
- Cell-mediated immunity, association with infections in chronic lymphocytic leukemia, 241
- Cerebellar degeneration, paraneoplastic, 275-278
  - differential diagnosis, 277
  - in encephalomyelitis, 279
  - pathogenesis, 277-278
  - treatment, 278
- Cerebrospinal fluid, in diagnosis of neoplastic meningitis
  - examination of, 314
  - flow studies of, 316
- Cetuximab
  - chemotherapy-related toxicity of
    - dermatologic toxicity, 93
    - lung injury, 102
  - for targeted cancer therapy, 372-373
- Checkpoint kinases, as targets for cancer therapy, 441
- Chemical genetics, and unknown tubulin-associated targets, 443
- Chemical genomics, in identifying genotype-selective anti-cancer agents, 516-517
- Chemoimmunotherapy, for chronic lymphocytic leukemia, 206
  - relation to increased infection risk, 245
- Chemoprevention, for breast cancer in high-risk women
  - benign lesions and genetic predisposition, 643-644
  - guidelines, 644-645
  - ongoing studies, 645
  - patient monitoring, 645
  - tamoxifen, 642-643
- Chemotherapy
  - adjuvant, for renal cell carcinoma, 577-578
  - combination with anti-PKC cancer therapy, 474
  - combined with ovarian ablation and suppression, in premenopausal women with breast cancer, 659-660
  - interaction with AEDs, 339
  - for neoplastic meningitis
    - intrathecal, 318-320
    - systemic, 320-321
  - neurotoxicity of
    - alkylating agents, 324-327
    - antimetabolites, 327-328
    - bortezomib, 330
    - corticosteroids, 329
    - interferons, 329
    - interleukins, 330
    - L-asparaginase, 329
    - monoclonal antibodies, 330
    - plant alkaloids, 328-329
    - supportive therapies, 330
    - tamoxifen, 329
    - thalidomide, 329
  - and other agents for brain metastases, 303-304
  - resistance to, role of Raf-1, 398
  - synergy with anti-EGFR cancer therapy, 377-378
  - toxicity of, 1
    - cardiotoxicity
      - anthracyclines, 2-7
      - monitoring during treatment, 5-7
      - prognosis and treatment, 10
      - taxanes, 7-8
      - trastuzumab, 8-10
    - dermatologic toxicity
      - antimetabolites, 90-91
      - cetuximab, 93
      - gefitinib, 93
      - imatinib mesylate, 92-93
      - monoclonal antibodies, 91-92
      - polyethylene glycol-coated liposomal doxorubicin, 89-90

Chemotherapy (*Continued*)

- taxanes, 86-89
- thalidomide, 91
- topoisomerase I inhibitors, 91
- vinorelbine, 91
- gastrointestinal toxicity
  - candidiasis, 114
  - constipation, 114
  - diarrhea, 114
  - effects of nutritional support, 115
  - enteritis, 114-115
  - esophagitis, 114
  - malabsorption, 113-114
  - mucositis, 112-113
  - nausea and vomiting, 106-112
- hepatotoxicity
  - antimetabolites, 53-55
  - antitumor antibiotics, 55-56
  - biologic response modifiers, 58
  - combination chemotherapy regimens, 59-60
  - DNA covalent binding agents, 51-53
  - hepatic veno-occlusive disease, 60
  - hormonal agents, 59
  - microtubule-targeting drugs, 56-57
  - miscellaneous antineoplastic agents, 58
  - supportive care agents, 60
  - target-specific antineoplastic agents, 57-58
  - topoisomerase inhibitors, 57
- lung injury
  - alkylating agents, 101-102
  - antimetabolites, 100-101
  - bronchospasm, 98
  - cytotoxic antibiotics, 98-100
  - inflammatory interstitial pneumonitis, 98
  - microtubule inhibitors, 102
  - miscellaneous agents, 103-104
  - pleural effusions, 98
  - pulmonary edema, 98
  - small molecule-targeted therapeutic agents, 102-103
- myelotoxicity
  - anemia, 78-82
  - neutropenia, 74-77
  - thrombocytopenia, 82-83
- renal toxicity
  - alkylating agents, 70-71
  - antimetabolites, 71-72
  - evaluation of renal function, 68
  - platinum compounds, 69-72
  - risk factors, 68-69
- vascular toxicity
  - Budd-Chiari syndrome, 124
  - capillary-leak syndrome, 128
  - hepatic veno-occlusive disease, 122-124
  - hypotension and hypertension, 127
  - leukocytoclastic vasculitis, 128
  - myocardial ischemia and infarction, 124-125
  - palmar-plantar erythrodysesthesia, 128
  - pathogenesis of, 128-129
  - pulmonary veno-occlusive disease, 121-122
  - Raynaud's phenomenon, 124
  - retinal-vessel toxicity, 128
  - thrombosis and thromboembolic complications, 126-127
  - thrombotic microangiopathic syndrome, 125-126
- traditional, 408
- v neoadjuvant endocrine therapy, for locally advanced breast cancer, 652-653
- v ovarian ablation and suppression, in premenopausal women with breast cancer, 659
- Chemotherapy extravasation
  - initial management, 141
  - pharmacologic management, 141-142
  - prevention, 139-140
  - surgery, 142
- Chemotherapy-induced peripheral neuropathy
  - clinical challenges in diagnosis and quantification, 30
  - clinical diagnostic features, 20-21
  - clinical features associated with therapeutic agent
    - Abraxane, 27
    - bortezomib, 29
    - carboplatin, 24, 27-28
    - cisplatin, 24, 27-28
    - Cremophor EL, 26-27
    - cytarabine, 29-30
    - docetaxel, 27-28
    - etoposide, 29-30
    - interferon alfa, 29-30
    - oxaliplatin, 24-25, 41-42
    - paclitaxel, 25-28
    - procarbazine, 29-30
    - thalidomide, 29
    - vinca alkaloids, 28-29
  - common and serious clinical problem, 23-24
  - design and endpoint considerations for clinical trials, 42-43
  - diagnostic classification, 21-23
  - evaluation methods for, selection, standardization, and reliability determination
    - patient-based methods, 36-39
    - physician-based methods, 33-36
    - quantitative sensory tests and electrophysiologic measurements in combination with neurologic evaluations, 31-33
  - pathogenesis and pathophysiology, 18-20
  - prevention and treatment
    - amifostine, 40-41
    - calcium/magnesium infusions, 42
    - carbamazepine, 41-42
    - gabapentin, 41
    - glutamate, 41
    - glutamine, 41
    - glutathione, 41
    - nerve growth factor and analogs, 39-40
    - Tavocept, 42
- Chlorambucil, chemotherapy-related toxicity of
  - hepatotoxicity, 52
  - lung injury, 101
- Chromophobe renal cell carcinoma, pathology of, 537-538
- Chromosome 11q abnormalities, in Richter's syndrome in chronic lymphocytic leukemia, 251
- Chronic lymphocytic leukemia, 149
  - angiogenesis in, 176-177
    - abnormal, therapeutic targeting, 180-181
    - prognostic implications, 179-180
  - angiogenic cytokines in, biologic implications, 178-179
  - autoimmunity in
    - clinical features, 231
    - pathogenesis, 231-233
    - treatment, 233-236
  - B-cell, see B-cell chronic lymphocytic leukemia
  - correcting immune defects in, 221-222
  - epigenetics in
    - aberrant promoter hypermethylation, 161-162
    - DNA methylation, 162-163
    - genome-wide and gene-specific hypomethylation, 160-161
    - therapy, 163
  - familial, see Familial chronic lymphocytic leukemia
  - frontline therapy for
    - alemtuzumab, 204
    - alkylating agent-based, 203



- Chronic lymphocytic leukemia, 149 (*Continued*)
- chemoimmunotherapy, 206
  - indications, 203
  - prognostic factors for treatment response, 206-207
  - purine analogue with alkylating agent, 205-206
  - purine analogues, 203-204
  - rationale approach and objectives, 202-203
  - residual disease, 207
  - rituximab, 204-205
- infections in
- cell-mediated immunity and, 241
  - complement defects and, 241
  - hypogammaglobulinemia and, 240-241
  - neutrophil and phagocytic defects, 241-242
  - pathogenesis, 240
  - prevention, 246-247
  - spectrum of, 242-245
- miRNAs in
- association with prognostic factors and progression, 170
  - differential expression, 169-170
  - germ-line mutations, 170-171
  - miR-15a and miR-16-1 genes in CD5<sup>+</sup> cells, 168
  - model of cancer initiation and progression, 171-172
  - and post-translational inhibition of BCL2, 171
  - regulatory functions, 168-169
- monoclonal antibody therapy, 224, 226
- neovascularization in, prognostic implications, 179-180
- relapsed, *see* Relapsed chronic lymphocytic leukemia
- Richter's syndrome in
- diagnostic evaluation, 252-253
  - etiology and oncogenesis, 250-252
  - incidence, 252
  - prognostic factors, 253
  - symptoms and signs, 252
  - treatment, 253-254
- risk stratification in
- clinical staging systems, 186
  - evaluation of autologous and allogeneic stem cell transplantation, 192-193
  - genetic parameters, 187-191
  - markers of tumor burden, 186-187
  - prognostic factors, 186-191
  - progression in early-stage chronic lymphocytic leukemia, 191-192
  - response to treatment and survival in advanced-stage chronic lymphocytic leukemia, 192
  - serum parameters, 187
- serum/plasma levels of angiogenic factors in, 176-177
- stem cell transplantation and graft-versus-leukemia effect, 226
- stromal cells in, biologic implications, 178-179
- vaccine development for
- altered tumor as antigen source, 223
  - dendritic cells, 223-224
  - gene therapy, 224
  - idiotype, 222
  - other tumor antigens, 222-223
  - trioma cells, 224
- VEGF in
- autocrine pathway, 177-178
  - biologic implications, 178-179
- Cigarette smoking, and renal cell carcinoma, 529
- CIPN, *see* Chemotherapy-induced peripheral neuropathy
- Cisplatin, chemotherapy-related toxicity of
- CIPN, clinical features of, 24
  - v carboplatin, 27-28
  - renal toxicity, 69-70
- Cladribine
- chemotherapy-related hepatotoxicity of, 55
  - and increased infection risk in chronic lymphocytic leukemia, 243
- Clear cell renal cell carcinoma, pathology of, 534-535
- Clone cells, in b-cell chronic lymphocytic leukemia, 153
- Clonidine, for menopausal vasomotor symptoms in breast cancer survivors, 699
- c-MET, as target of renal cell carcinoma therapy, 592
- c-MYC oncogene, TMPyP4 inhibition via G-quadruplex silencer element, 368, 498-510
- relation to oncogenesis, 499
- Coagulopathy, associated with lymphoma and leukemia, 345
- Cognition, effects of aromatase inhibitors on, 693
- Collecting duct carcinoma, renal, pathology of, 538-539
- Combination chemotherapy regimens, chemotherapy-related hepatotoxicity of, 59-60
- Complement defects, association with infections in chronic lymphocytic leukemia, 241
- Cone dysfunction, cancer-associated, 284
- Constipation, chemotherapy-related, 114
- Corticosteroids
- in cancer chemotherapy, neurotoxicity of, 329
  - and cytotoxic drugs, for treatment of autoimmunity in chronic lymphocytic leukemia, 234
- Cranial irradiation, prophylactic, for brain metastases, 304
- Cranial nerves, paraneoplastic syndromes of
- bilateral diffuse uveomelanocytic proliferation, 284-285
  - cancer-associated cone dysfunction, 284
  - melanoma-associated retinopathy, 284
  - optic neuropathy, 285
  - visual, 282-284
- Cremophor EL, clinical features of CIPN associated with, 26-27
- Cryoglobulinemia, peripheral neuropathies associated with, 288
- CSF, *see* Cerebrospinal fluid
- CT-2103, for targeted cancer therapy, 425-426
- CXC cytokine receptor 4, as target of renal cell carcinoma therapy, 592
- Cyclin D1/cdk4, as target of renal cell carcinoma therapy, 591-592
- Cyclophosphamide
- chemotherapy-related toxicity of
    - hepatotoxicity, 51-52
    - lung injury, 101
    - renal toxicity, 70  - for fludarabine-refractory chronic lymphocytic leukemia and fludarabine and rituximab, 213-214
  - with pentostatin or fludarabine, 212-213
- Cyclosporine, for autoimmunity in chronic lymphocytic leukemia, 234
- Cytarabine
- in cancer chemotherapy, neurotoxicity of, 327-328
  - chemotherapy-related toxicity of
    - CIPN, clinical features of, 29-30
    - hepatotoxicity, 54
    - lung injury, 100
- Cytokines, angiogenic, biologic implications in chronic lymphocytic leukemia, 178-179
- Cytotoxic antibiotics, causing chemotherapy-related lung injury
- bleomycin, 98-99
  - dactinomycin, 100
  - doxorubicin, 100
  - mitomycin, 99-100
- Cytotoxic drugs, and corticosteroids, for treatment of autoimmunity in chronic lymphocytic leukemia, 234
- Dacarbazine, chemotherapy-related hepatotoxicity of, 53
- Dactinomycin, chemotherapy-related toxicity of
- hepatotoxicity, 56
  - lung injury, 100
- Dendritic cell vaccines, for renal cell carcinoma, 618-619
- Dendritic cells, in vaccine development for chronic lymphocytic leukemia, 223-224
- Dermatologic toxicity, chemotherapy-related
- antimetabolites, 90-91
  - bortezomib, 93-94
  - cetuximab, 93

- Dermatologic toxicity, chemotherapy-related (*Continued*)
- gefitinib, 93
  - imatinib mesylate, 92-93
  - monoclonal antibodies, 91-92
  - polyethylene glycol-coated liposomal doxorubicin, 89-90
  - taxanes, 86-89
  - thalidomide, 91
  - topoisomerase I inhibitors, 91
  - vinorelbine, 91
- Dextrazoxane, cardiotoxicity of, 4-5
- DHA-paclitaxel, for targeted cancer therapy, 426-427
- Dialysis, and renal cell carcinoma, 530-531
- Diarrhea, chemotherapy-related, 114
- Diaziquone, chemotherapy-related renal toxicity of, 72
- Diet, and renal cell carcinoma, 530
- Dimesna, *see* Tavocept
- 17-Dimethylaminoethylamino-17-demethoxygeldanamycin, as Hsp90 inhibitor for targeted cancer therapy, 459-462
- Discodermolide, for targeted cancer therapy, 430
- Disodium 2,2'-dithiobisethane sulfonate, *see* Tavocept
- 17DMAG, *see* 17-Dimethylaminoethylamino-17-demethoxygeldanamycin
- DNA covalent binding agents, chemotherapy-related hepatotoxicity of
- busulfan, 53
  - chlorambucil, 52
  - cyclophosphamide, 51-52
  - dacarbazine, 53
  - melfalan, 52-53
  - nitrosoureas, 53
  - platinum agents, 53
  - procarbazine, 53
- DNA methylation, 157-159
- in chronic lymphocytic leukemia
    - aberrant, *see* Aberrant DNA methylation
    - and clinical correlation, 162-163
    - familial, *see* Familial chronic lymphocytic leukemia
  - cross-talk between histone modifications and, 159
- Docetaxel
- in cancer chemotherapy, neurotoxicity of, 328
  - chemotherapy-related toxicity of
    - CIPN, clinical features of, 27
    - v* paclitaxel, 27-28
  - dermatologic toxicity, 86-89
- Dorsal root ganglia, paraneoplastic encephalomyelitis, 279
- Doxorubicin, chemotherapy-related toxicity of
- cardiotoxicity, liposomal formulations of, 5
  - dermatologic toxicity, polyethylene glycol-coated liposomal formulations of, 89-90
  - hepatotoxicity, 56
  - lung injury, 100
- Drug-sensitive relapsed chronic lymphocytic leukemia, treatment of, 211
- Ductal carcinoma-in-situ, tamoxifen for, 647-649
- EBV, *see* Epstein-Barr virus
- Edema, pulmonary, chemotherapy-related, 98
- Eg5, *see* KSP
- EGFR-targeting agents, *see* Anti-EGFR agents
- Embryonic stem cells, and vaccines for renal cell carcinoma, 621
- Emulsions, of paclitaxel, for targeted cancer therapy, 427
- Encephalomyelitis, paraneoplastic
- antibodies and, 280
  - autonomic neuropathy, 279-280
  - brainstem encephalitis, 279
  - cerebellar degeneration, 279
  - dorsal root ganglia, 279
  - hippocampus, 278-279
  - hypothalamus, 279
  - spinal cord, 279
- Endocrine therapy, *see* Hormonal therapy
- Endomyocardial biopsy, in monitoring of anthracycline cardiotoxicity, 6
- Enteritis, chemotherapy-related, 114-115
- Epidermal growth factor receptor, as target of renal cell carcinoma therapy, 591
- Epidermal growth factor receptor-targeting agents, *see* Anti-EGFR agents
- Epidural spinal cord compression
- due to leukemia and lymphoma, 343
  - metastatic, management of
    - historical review, 307-308
    - radiotherapy, 310
    - randomized trials, 308-309
    - surgery, 309-310
    - time to motor weakness as prognostic variable, 308
- Epigenetics
- in chronic lymphocytic leukemia
    - aberrant promoter hypermethylation, 161-162
    - cancer therapy, 163
    - DNA methylation, 162-163
    - genome-wide and gene-specific hypomethylation, 160-161
    - cross-talk between histone modifications and DNA methylation, 159
    - deregulation in cancer, 158-159
    - DNA methylation, 157-159
    - post-translational modification of histone tail, 158-159
- Epirubicin, cardiotoxicity of, 4
- Epithelial tumors, of the kidney, *see* Renal epithelial neoplasms
- Epothilones, for targeted cancer therapy, 428-430
- Epstein-Barr virus, in Richter's syndrome in chronic lymphocytic leukemia, 251-252
- Erlotinib
- causing chemotherapy-related lung injury, 103
  - for targeted cancer therapy, 373-375
- Erythropoiesis stimulators, in cancer chemotherapy, neurotoxicity of, 330
- Erythropoietin
- recombinant, in cancer chemotherapy, neurotoxicity of, 330
  - as target of renal cell carcinoma therapy, 591
- Esophagitis, chemotherapy-related, 114
- Estrogen receptor, in breast cancer, 631-632
- activation in the absence of estrogen, 638
  - estrogen receptor alpha in, 633
  - estrogen receptor beta in, 633-634
  - gene activation by *r*, 634-635
  - as marker of sensitivity to neoadjuvant endocrine therapy, 653-654
  - signal transduction, 638
- Estrogen therapy, for breast cancer, hormesis in, 709
- Etoposide, chemotherapy-related toxicity of
- CIPN, clinical features of, 29-30
  - hepatotoxicity, 57
- Extravasation, of chemotherapeutic agents
- initial management, 141
  - pharmacologic management, 141-142
  - prevention, 139-140
  - surgery, 142
- Familial chronic lymphocytic leukemia
- characteristics of, 195-197
  - and DNA methylation, 162
  - gene identification studies, 198-199
  - genetic models of, 197-198
  - genetic predisposition to, 195
  - and germ-line mutations of miRNAs, 170-171
- Fertility, preservation in premenopausal breast cancer patients, 664-669
- Filgrastim, causing chemotherapy-related lung injury, 103
- Flavopiridol, for fludarabine-refractory chronic lymphocytic leukemia, 214-215
- Fludarabine
- chemotherapy-related hepatotoxicity of, 55
  - for fludarabine-refractory chronic lymphocytic leukemia
    - and cyclophosphamide and rituximab, 213-214
    - or pentostatin with cyclophosphamide, 212-213
  - and increased infection risk in chronic lymphocytic leukemia, 242-243



- Fludarabine monophosphate, causing chemotherapy-related lung injury, 100
- Fludarabine-refractory chronic lymphocytic leukemia, 211-212
- new antibodies and biologic therapies, 216
  - new effective targeted therapies
    - flavopiridol, 214-215
    - lenalidomide, 215
- small molecules in early clinical trials, 215-216
- standard treatment strategies
- alemtuzumab (Campath-1H), 212-214
  - alternative nucleoside analogs, 214
  - fludarabine, cyclophosphamide, and rituximab, 213-214
  - fludarabine or pentostatin with cyclophosphamide, 213
  - high-dose methylprednisolone, 214
  - rituximab, 214
- Fluorodeoxyuridine, chemotherapy-related hepatotoxicity of, 54
- 5-Fluorouracil
- in cancer chemotherapy, neurotoxicity of, 328
  - chemotherapy-related hepatotoxicity of, 54
- Gabapentin
- for menopausal vasomotor symptoms in breast cancer survivors, 699-700
  - for prevention and treatment of CIPN, 41
- Gastrointestinal toxicity, chemotherapy-related
- candidiasis, 114
  - constipation, 114
  - diarrhea, 114
  - effects of nutritional support, 115
  - enteritis, 114-115
  - esophagitis, 114
  - malabsorption, 112-113
  - mucositis, 112-113
  - nausea and vomiting
    - clinical syndromes, 107-109
    - pathophysiology, 107
    - predictors, 109
    - treatment, 109-112
- Gefitinib
- chemotherapy-related toxicity of
    - dermatologic toxicity, 93
    - hepatotoxicity, 57
    - lung injury, 103
- plus SU11248, for renal cell carcinoma, 600
- for targeted cancer therapy, 373-375
- Gemcitabine, chemotherapy-related toxicity of
- dermatologic toxicity, 90-91
  - hepatotoxicity, 55
  - lung injury, 100-101
  - renal toxicity, 71
- Gemtuzumab, chemotherapy-related hepatotoxicity of, 57
- Gene identification studies, in familial chronic lymphocytic leukemia, 198-199
- Gene therapy
- for neoplastic meningitis, 321
  - in vaccine development for chronic lymphocytic leukemia, 224
- Gene-modified tumor cell vaccines, for renal cell carcinoma, 618
- Genetic models, of familial chronic lymphocytic leukemia, 197-198
- Genetic predisposition, to familial chronic lymphocytic leukemia, 195
- Genomic aberration, relation to  $V_H$  mutation status in chronic lymphocytic leukemia, 188-189
- Genomic instability, and unknown tubulin-associated targets, 443-445
- Genomics
- chemical, in identifying genotype-selective anti-cancer agents, 516-517
  - miRNAs in chronic lymphocytic leukemia
    - association with prognostic factors and progression, 170
    - differential expression, 169-170
    - germ-line mutations, 170-171
    - miR-15a and miR-16-1 genes in CD5<sup>+</sup> cells, 168
    - model of cancer initiation and progression, 171-172
- Genomics (Continued)
- and post-translational inhibition of BCL2, 171
  - regulatory functions, 168-169
- Germ-line mutation, of miRNAs, and familial chronic lymphocytic leukemia, 170-171
- Glucocorticoids, interaction with AEDs, 339
- Glutamate, for prevention and treatment of CIPN, 41
- Glutamine, for prevention and treatment of CIPN, 41
- Glutathione, for prevention and treatment of CIPN, 41
- Gossypol derivatives, for Bcl-2 inhibition in targeted cancer therapy, 453
- G-quadruplex silencer element, in TMPyP4 inhibition of c-MYC oncogene, 368, 498-510
- Graft-versus-host disease, chronic, and neurotoxicity of bone marrow and stem cell transplantation, 357
- Graft-versus-leukemia effect, and stem cell transplantation in chronic lymphocytic leukemia, 226
- Growth factor therapy, for chemotherapy-related myelotoxicity
- neutropenia, 75-76
  - thrombocytopenia, 83
- Guillain-Barré syndrome, paraneoplastic, 288
- GW786034, for renal cell carcinoma, 602-603
- GX15-070, for Bcl-2 inhibition in targeted cancer therapy, 453
- HA 14-1, for Bcl-2 inhibition in targeted cancer therapy, 453
- Head and neck cancers, neurologic complications of
- adenoid cystic carcinoma, 349
  - hypopharyngeal tumors, 349-350
  - nasopharyngeal tumors, 348-349
  - paragangliomas, 350
  - parapharyngeal tumors, 349-350
  - salivary gland tumors, 349
- Heat shock protein 90, as target for cancer therapy, 367, 457-462
- cancer biology and, 459
  - inhibitors
    - clinical experience, 461-462
    - development, 459-461
- Heat shock protein vaccines, for renal cell carcinoma, 619-620
- Hematologic neoplasms, angiogenic factors in, 175-176
- Hematopoietic cells
- angiogenic factors in, 175-176
  - normal, v chronic lymphocytic leukemia cells, differential expression of miRNAs, 169-170
- Hepatic veno-occlusive disease, chemotherapy-related, 60, 122-124
- Hepatotoxicity, chemotherapy-related
- antimetabolites, 53-55
    - antitumor antibiotics, 56
    - biologic response modifiers, 58
    - combination chemotherapy regimens, 59-60
    - DNA covalent binding agents, 51-53
    - hormonal agents, 59
    - microtubule-targeting drugs, 56-57
    - miscellaneous antineoplastic agents, 58
    - supportive care agents, 60
    - target-specific antineoplastic agents, 57-58
    - topoisomerase inhibitors, 57
- HER2, structural features and dimerization properties, 386-388
- HER2 epitope-targeting agents, *see* Anti-HER2 agents
- HER growth factor receptors, in breast cancer, 636
- as marker of sensitivity to neoadjuvant endocrine therapy, 653-654
- Hereditary leiomyomatosis and renal cell cancer, genetic basis of, 548-550
- Hereditary papillary renal cell carcinoma, genetic basis of, 546-547
- Her-2/neu, status of, role in selection of endocrine therapy for breast cancer, 681-686
- HIF-1, *see* Hypoxia-inducible factor-1
- High-dose methylprednisolone, for fludarabine-refractory chronic lymphocytic leukemia, 214
- Hippocampus, paraneoplastic limbic encephalitis, 278-279
- Histone deacetylases, in breast cancer, 634
- Histones, post-translational modification of, 158-159

- Hormesis  
  in androgen therapy for prostate cancer, 708-709  
  in estrogen therapy for breast cancer, 709  
  in immunotherapy for cancer, 710
- Hormonal therapy  
  adjuvant, for renal cell carcinoma, 577  
  for breast cancer, 629-630  
    adjuvant, in premenopausal women  
      ovarian ablation and suppression, 658-660  
      recommendations from consensus meetings, 660  
      research directions, 660-662  
      tamoxifen, 657  
  neoadjuvant, for locally advanced breast cancer  
    ACOSOG Z1031 Trial, 654-655  
    biomarker analysis in, 653-654  
    as short-term surrogate to predict long-term outcomes, 653  
    tamoxifen, 650-651  
    third-generation aromatase inhibitors, 651-652  
    v chemotherapy, 652-653  
  role of Her-2/neu status, 681-686  
  chemotherapy-related hepatotoxicity of, 59
- Hormone-dependent cancer, role of Raf-1 in, 396
- Hormones, and renal cell carcinoma, 530
- Hsp90, see Heat shock protein 90
- 5-HT<sub>3</sub>-receptor antagonists, for treatment of chemotherapy-related nausea and vomiting, 110-111
- Hydroxyurea, chemotherapy-related toxicity of  
  hepatotoxicity, 58  
  lung injury, 103
- Hypermethylation, aberrant promoter, in chronic lymphocytic leukemia, 161-162
- Hypertension  
  chemotherapy-related, 127  
  and renal cell carcinoma, 529
- Hypogammaglobulinemia, association with infections in chronic lymphocytic leukemia, 240-241
- Hypomethylation, genome wide and gene-specific, in chronic lymphocytic leukemia, 160-161
- Hypopharyngeal tumors, neurologic complications of, 349-350
- Hypotension, chemotherapy-related, 127
- Hypothalamus, paraneoplastic encephalomyelitis, 279
- Hypoxia inducible factor, in renal cell carcinoma  
  mTOR and, 608-609  
  as prognostic marker, 570  
  role in, 590  
  targeting of growth factors responsive to, 590-591
- Hypoxia-inducible factor-1, as target for cancer therapy, 367  
  endogenous inhibitors  
    OS-9 protein, 490-491  
    p53 tumor suppressor protein, 490  
    SART1/HAF, 491  
  expression in cancer, 489-490  
  molecular and cellular biology, 487  
  pharmacologic targeting, 491-493  
  regulation, 487-489
- Idiotypic vaccines, for chronic lymphocytic leukemia, 222
- Ifosfamide  
  in cancer chemotherapy, neurotoxicity of, 326-327  
  chemotherapy-related toxicity of  
    lung injury, 101  
    renal toxicity, 70
- Imatinib, chemotherapy-related toxicity of  
  dermatologic toxicity, 92-93  
  hepatotoxicity, 57-58  
  lung injury, 102-103
- Immunity, cell-mediated, association with infections in chronic lymphocytic leukemia, 241
- Immunocytotoxic, intrathecal, for neoplastic meningitis, 320
- Immunoglobulin, intravenous, for autoimmunity in chronic lymphocytic leukemia, 234
- Immunoglobulin receptors, in b-cell chronic lymphocytic leukemia  
  antigen and progression, 152  
  antigenic element and, 151-152  
  circulating leukemia-like cells, 152-153
- Immunoglobulin therapy, for infection prevention in chronic lymphocytic leukemia, 246
- Immunophenotype  
  of B-cell prolymphocytic leukemia, 260  
  of T-cell prolymphocytic leukemia, 258
- Immunosuppression  
  long-term, in bone marrow and stem cell transplantation, neurotoxicity associated with, 356-357  
  tumor-mediated, in renal cell carcinoma, reversal of  
    immature myeloid cells, 621-622  
    regulatory T cells, 622
- Immunotherapy, adjuvant, for renal cell carcinoma, 578
- Infections  
  associated with lymphoma and leukemia, 345  
  in chronic lymphocytic leukemia  
    cell-mediated immunity and, 241  
    complement defects and, 241  
    hypogammaglobulinemia and, 240-241  
    neutrophil and phagocytic defects and, 241-242  
    pathogenesis, 240  
  prevention of  
    antimicrobial prophylaxis, 246-247  
    immunoglobulin therapy, 246  
    vaccination, 246  
  spectrum of  
    alemtuzumab, 244-245  
    alkylating agents, 242  
    chemoimmunotherapy, 245  
    cladribine, 243  
    fludarabine, 242-243  
    monoclonal antibodies, 244  
    pentostatin, 243-244  
    purine analogues, 242  
  transmitted by transplanted tissue, 357
- Inflammatory interstitial pneumonitis, chemotherapy-related, 98
- Inflammatory myopathies, paraneoplastic, 291-292
- Ingenol derivatives, as PKC modulators for targeted cancer therapy, 473
- Interferon  $\alpha$   
  chemotherapy-related toxicity of  
    CIPN, clinical features of, 29-30  
    hepatotoxicity, 58  
  for renal cell carcinoma  
    adjuvant therapy, 578  
    with or without high-dose interleukin-2 for metastatic carcinoma, 584-585  
    plus SU11248, 600
- Interferons, in cancer chemotherapy, neurotoxicity of, 329
- Interleukin-2  
  chemotherapy-related toxicity of  
    hepatotoxicity, 58  
    lung injury, 103  
  for renal cell carcinoma  
    adjuvant therapy, 578-579  
    high-dose therapy for metastatic carcinoma, 583-586
- Interleukins, in cancer chemotherapy, neurotoxicity of, 330
- Intrathecal biologic agents, antibodies, and immunoconjugates, for neoplastic meningitis, 320
- Intrathecal chemotherapy, for neoplastic meningitis, 318-319  
  newer and investigational, 319-320
- Intravenous immunoglobulin, for autoimmunity in chronic lymphocytic leukemia, 234
- Investigational agents, for multitargeted cancer therapy  
  mTOR inhibitors, 413-414

- Investigational agents, for multitargeted cancer therapy (*Continued*)  
multitargeted TKIs  
  sorafenib tosylate, 415  
  sunitinib malate, 415-417  
small molecules, 414
- Irinotecan, chemotherapy-related toxicity of  
dermatologic toxicity, 91  
hepatotoxicity, 57  
lung injury, 104
- ISIS 5132, *see* Antisense oligonucleotides
- Kidney neoplasms, genetic basis of  
Birt-Hogg-Dubé syndrome, 547-548  
clinical management and, 548  
hereditary leiomyomatosis and renal cell cancer, 548-550  
hereditary papillary renal cell carcinoma, 546-547  
von Hippel-Lindau disease, 544-546
- Kidney transplantation  
in cancer, neurotoxicity of, 359  
and renal cell carcinoma, 530-531
- KSP, as target for cancer therapy, 442
- Lactate dehydrogenase, serum level as marker of tumor burden in chronic lymphocytic leukemia, 186-187
- Lambert-Eaton myasthenic syndrome, paraneoplastic, 288-289
- Left ventricular ejection fraction assessment, in monitoring of anthracycline cardiotoxicity, 6-7
- Lenalidomide, for fludarabine-refractory chronic lymphocytic leukemia, 215
- Leptomeningeal metastasis, of leukemia and lymphoma, 343
- Leukemia  
chronic lymphocytic, *see* Chronic lymphocytic leukemia  
  B-cell, *see* B-cell chronic lymphocytic leukemia  
neurologic complications of  
  coagulopathy, 345  
  direct effects  
    epidural spinal cord compression, 343  
    leptomeningeal metastasis, 343  
    mass lesions, 342-343  
    peripheral nerve and nerve root involvement, 343  
    skeletal muscle involvement, 343  
    vascular, 343-344  
  indirect effects  
    infections, 345  
    paraneoplastic syndromes, 344-345  
  metabolic abnormalities, 345-346  
  treatment effects, 346  
prolymphocytic  
  B-cell, *see* B-cell prolymphocytic leukemia  
  T-cell, *see* T-cell prolymphocytic leukemia
- Leukocytoclastic vasculitis, chemotherapy-related, 128
- Limbic encephalitis, paraneoplastic, 278-279
- Lipids, effects of aromatase inhibitors on, 691-692
- Liposomal doxorubicin formulations  
cardiotoxicity, 5  
dermatologic toxicity, polyethylene glycol-coated, 89-90
- Liver transplantation, in cancer, neurotoxicity of, 358-359
- Loss-of-function mutations, of tumor-suppressor genes, as targets for anti-cancer drug development, 368  
chemical genomics, 516-517  
RNAi gene silencing, 517  
synthetic lethality, 514-516
- Low-molecular-weight EGFR tyrosine kinase inhibitors, for targeted cancer therapy, 373-375
- Lung injury, chemotherapy-related  
alkylating agents, 101-102  
antimetabolites, 100-101  
bronchospasm, 98  
cytotoxic antibiotics, 98-100  
inflammatory interstitial pneumonitis, 98
- Lung injury, chemotherapy-related (*Continued*)  
microtubule inhibitors, 102  
miscellaneous agents, 103-104  
pleural effusions, 98  
pulmonary edema, 98  
small molecule-targeted therapeutic agents, 102-103
- LVEF, *see* Left ventricular ejection fraction
- Lymph nodes  
neovascularization in chronic lymphocytic leukemia, 176-177  
in prognosis of renal cell carcinoma, 565
- Lymphocyte count, as marker of tumor burden in chronic lymphocytic leukemia, 186-187
- Lymphocyte doubling time, as marker of tumor burden in chronic lymphocytic leukemia, 186-187
- Lymphocytic leukemia, chronic, *see* Chronic lymphocytic leukemia  
  B-cell, *see* B-cell chronic lymphocytic leukemia
- Lymphoma  
neurologic complications of  
  coagulopathy, 345  
  direct effects, 342-344  
  indirect effects, 344-345  
  metabolic abnormalities, 345-346  
  treatment effects, 346  
in organ transplant recipients, 357-358
- Magnesium/calcium infusions, for acute oxaliplatin neuropathy, 42
- Malabsorption, chemotherapy-related, 112-113
- Mammalian target of rapamycin inhibitors  
for multitargeted cancer therapy, 413-414  
for renal cell carcinoma, 607-609  
  clinical development, 609-610  
  future clinical trial designs, 611-612  
  patient selection using molecular criteria, 610-611
- Matrix metalloproteinases, as targets of renal cell carcinoma therapy, 592
- Mcl-1-targeting agents, *see* Anti-Mcl-1 agents
- Mechlorethamine, for management of chemotherapy extravasation, 142
- Medullary carcinoma, renal, pathology of, 538-539
- MEK inhibitors, *see* Mitogen extracellular kinase inhibitors
- Melanoma  
  *b-ras* mutations in, 396-397  
  sorafenib tosylate for, 400-401
- Melanoma-associated retinopathy, 284
- Melphalan, chemotherapy-related toxicity of  
hepatotoxicity, 52-53  
lung injury, 101
- Meningeal biopsy, in diagnosis of neoplastic meningitis, 314
- Meningitis, neoplastic, *see* Neoplastic meningitis
- Menopause, treatment of symptoms in, among breast cancer survivors, 696-704  
cardiovascular disease, 703  
osteoporosis, 700-702  
urogenital atrophy, 702-703  
vasomotor symptoms  
  antidepressants, 699  
  black cohosh, 698-699  
  clonidine, 699  
  gabapentin, 699-700  
  phytoestrogens, 697-698  
  progestagens, 700  
  vitamin E succinate, 698
- 6-Mercaptopurine, chemotherapy-related hepatotoxicity of, 53
- Metabolic diseases, associated with leukemia and lymphoma, 345-346
- Metastasis, in prognosis of renal cell carcinoma, 565-566
- Metastatic epidural spinal cord compression, management of  
historical review, 307-308  
radiotherapy, 310  
randomized trials, 308-309  
surgery, 309-310  
time to motor weakness as prognostic variable, 308

- Metastatic renal cell carcinoma  
 high-dose interleukin-2 therapy for, 583-584  
 clinical predictors of response, 585  
 pathologic and molecular predictors of response, 585-586  
 randomized trials with or without interferon alfa, 584-585  
 rationale for "Select" Trial, 586  
 surgery for, 557-559
- Methotrexate  
 in cancer chemotherapy, neurotoxicity of, 327  
 chemotherapy-related toxicity of  
 hepatotoxicity, 55  
 lung injury, 100  
 renal toxicity, 71
- Methylprednisolone, high-dose, for fludarabine-refractory chronic lymphocytic leukemia, 214
- MicroRNAs  
 as Bcl-2 inhibitors for targeted cancer therapy, 452  
 in chronic lymphocytic leukemia  
 association with prognostic factors and progression, 170  
 germ-line mutations, 170-171  
 miR-15a and miR-16-1 genes in CD5<sup>+</sup> cells, 168  
 model of cancer initiation and progression, 171-172  
 and post-translational inhibition of BCL2, 171  
 regulatory functions, 168-169  
 v normal hematopoietic cells, differential expression of, 169-170
- Microsatellite instability, in Richter's syndrome in chronic lymphocytic leukemia, 251
- Microtubule inhibitors, causing chemotherapy-related lung injury, 102
- Microtubules, *see also* Anti-microtubule agents; Tubulin- polymerizing agents  
 mechanisms of disruption, 421-422
- Microtubule-targeting drugs, chemotherapy-related hepatotoxicity of  
 taxanes, 56-57  
 vinca alkaloids, 56
- Microvascular invasion, in prognosis of renal cell carcinoma, 567
- miRNAs, *see* MicroRNAs
- Mitogen extracellular kinase inhibitors, for targeted cancer therapy, 399
- Mitogen-activated protein kinase, in multitargeted cancer therapy, 407-417
- Mitomycin  
 chemotherapy-related toxicity of  
 hepatotoxicity, 56  
 lung injury, 99-100  
 renal toxicity, 71  
 for management of chemotherapy extravasation, 142
- Mitosis, and tubulin, 436-437
- Mitotic kinesins, as targets for cancer therapy, 430-431  
 KSP, 442  
 other potential targets, 442-443
- Mitoxantrone, chemotherapy-related hepatotoxicity of, 56
- M<sub>4</sub>N, *see* tetra-O-methyl nordihydroguareic acid
- Molecular chaperones, *see* Heat shock protein 90
- Molecular markers, in prognosis of renal cell carcinoma  
 adhesion molecules, 572  
 bcl-2 gene, 572  
 carbonic anhydrase IX, 570-571  
 hypoxia inducible factor, 570  
 p27 cell cycle regulator, 572  
 p53 tumor suppressor protein, 571  
 PTEN gene, 572  
 Smac/DIABLO, 572  
 von Hippel-Lindau tumor suppressor protein, 571
- Monoclonal antibodies (*Continued*)  
 relation to increased infection risk, 244  
 rituximab, 204-205  
 for targeted cancer therapy  
 anti-EGFR, 367, 372-373  
 anti-HER2, 367  
 peptidomimetics, 389-390  
 pertuzumab, 389  
 targeting multiple HER2 epitopes, 390-391  
 trastuzumab, 388-389
- Motor neuron disorders, paraneoplastic, 281-282
- Motor neuropathy, paraneoplastic, 286
- mTOR inhibitors, *see* Mammalian target of rapamycin inhibitors
- Mucositis, chemotherapy-related, 112-113
- Musculoskeletal system, effects of aromatase inhibitors on, 692-693
- Mutation  
 germ-line, of miRNAs, and familial chronic lymphocytic leukemia, 170-171  
 loss-of-function, of tumor-suppressor genes, as targets for anti-cancer drug development, 368  
 chemical genomics, 516-517  
 RNAi gene silencing, 517  
 synthetic lethality, 514-516  
 of V<sub>H</sub> genes, as prognostic marker in chronic lymphocytic leukemia, 187-188  
 global and targeted gene expression analyses, 190-191  
 relation to genomic aberrations, 188-189  
 surrogate markers, 189-190
- Myasthenia gravis, paraneoplastic, 289-291
- Myelitis, paraneoplastic, 280
- Myeloid cell leukemia-1-targeting agents, *see* Anti-Mcl-1 agents
- Myeloid cells, immature, in reversal of tumor-mediated immunosuppression in renal cell carcinoma, 621-622
- Myeloma, peripheral neuropathies associated with, 287
- Myelopathy, paraneoplastic  
 myelitis, 280  
 necrotizing, 280-281
- Myelotoxicity, chemotherapy-related  
 anemia  
 cost analysis, 81  
 incidence, 78  
 quality of life, 79-81  
 treatment, 78-79  
 tumor response, 81-82  
 neutropenia  
 economic consequences and clinical outcome, 76-77  
 growth factor therapy, 75-76  
 incidence mortality/risks/consequences, 74-75  
 quality of life, 77  
 thrombocytopenia, 82-83  
 growth factor therapy, 83
- Myocardial ischemia and infarction, chemotherapy-related, 124-125
- Myoclonus, paraneoplastic, 280
- Myopathy, paraneoplastic  
 cachectic, 292  
 inflammatory, 291-292  
 necrotizing, 292
- Nanoparticle albumin formulation of paclitaxel, *see* Abraxane
- Nasopharyngeal tumors, neurologic complications of, 348-349
- Nausea and vomiting, chemotherapy-related  
 clinical syndromes, 107-109  
 pathophysiology, 107  
 predictors, 109  
 treatment, 109-112  
 5-HT<sub>3</sub>-receptor antagonists, 110-111  
 neurokinin-1 receptor antagonists, 111-112
- Necrotizing myelopathy, paraneoplastic, 280-281
- Necrotizing myopathy, paraneoplastic, 292

- Neoplastic meningitis  
clinical features, 313-314  
diagnosis  
CSF examination, 314  
CSF flow studies, 316  
meningeal biopsy, 314  
neuroimaging, 314-315  
incidence, 313  
pathogenesis, 313  
prognosis, 316  
retreatment for recurrence, 321  
treatment  
gene therapy, 321  
intrathecal biologic agents, antibodies, and immunoconjugates, 320  
intrathecal chemotherapy, 318-320  
radioisotopes and radioimmunoconjugates, 320  
radiotherapy, 318  
standard, 316-317  
surgery, 317-318  
systemic chemotherapy, 320-321
- Neovascularization, in chronic lymphocytic leukemia  
of marrow and lymph nodes, 176-177  
prognostic implications, 179-180
- Nephrectomy, radical, *see* Radical nephrectomy
- Nephron-sparing surgery, for renal cell carcinoma  
adequacy of resection for, 556-557  
cost of care, 553-554  
elective, 552-553  
imperative indications, 552  
local control and cost-specific survival, 555  
morbidity, 553  
multifocality, 554-555  
preservation of renal function, 553  
quality of life, 553  
risk of benign tumors, 554  
tumor size, location, and histology, 555-556
- Nephrotoxicity, *see* Renal toxicity
- Nerve growth factor and analogs, for prevention and treatment of CIPN, 39-40
- Neuroimaging, in diagnosis of neoplastic meningitis, 314-315
- Neurokinin-1 receptor antagonists, for treatment of chemotherapy-related nausea and vomiting, 111-112
- Neurologic complications, *see also* Neurotoxicity  
of head and neck cancers  
adenoid cystic carcinoma, 349  
hypopharyngeal tumors, 349-350  
nasopharyngeal tumors, 348-349  
paragangliomas, 350  
parapharyngeal tumors, 349-350  
salivary gland tumors, 349  
of lymphoma and leukemia  
coagulopathy, 345  
direct effects, 342-344  
indirect effects, 344-345  
metabolic abnormalities, 345-346  
treatment effects, 346
- Neuromuscular junction diseases, paraneoplastic  
cachectic myopathy, 292  
inflammatory myopathies, 291-292  
Lambert-Eaton myasthenic syndrome, 288-289  
myasthenia gravis, 289-291  
necrotizing myopathy, 292  
neuromyotonia, 291
- Neuromyotonia, paraneoplastic, 291
- Neuropathy, peripheral, chemotherapy-induced, *see* Peripheral neuropathy, chemotherapy-induced
- Neurotoxicity  
of bone marrow transplantation in cancer, 329  
stem cell transplantation and, 352-357
- Neurotoxicity (*Continued*)  
of cancer chemotherapy  
alkylating agents, 324-327  
antimetabolites, 327-328  
other agents, 329-330  
plant alkaloids, 328-329  
supportive therapies, 330  
of organ transplantation in cancer  
infections transmitted by transplanted tissue, 357  
kidney transplantation, 359  
liver transplantation, 358-359  
post-transplantation lymphoproliferative disorder, lymphoma, and other secondary neoplasms, 357-358
- Neutropenia, chemotherapy-related  
economic consequences and clinical outcome, 76-77  
growth factor therapy, 75-76  
incidence mortality/risks/consequences, 74-75  
quality of life, 77
- Neutrophil defects, association with infections in chronic lymphocytic leukemia, 241-242
- Nitrogen mustard, *see* Mechlorethamine
- Nitrosoureas  
in cancer chemotherapy, neurotoxicity of, 327  
chemotherapy-related toxicity of  
hepatotoxicity, 53  
renal toxicity, 70-71
- Nucleoside analogs, alternative, for fludarabine-refractory chronic lymphocytic leukemia, 214
- Obesity, and renal cell carcinoma, 529
- Occupation, and renal cell carcinoma, 530
- Oligonucleotides, antisense, *see* Antisense oligonucleotides
- Oncocytoma, renal, pathology of, 538
- Oncogenesis  
and etiology of Richter's syndrome in chronic lymphocytic leukemia  
chromosome 11q abnormalities, 251  
EBV, 251-252  
microsatellite instability, 251  
trisomy 12, 251  
tumor-suppressor genes, 251  
relation of c-MYC oncoprotein, 499
- Oncophage vaccines, in adjuvant therapy for renal cell carcinoma, 579
- Opsoelonus, paraneoplastic, 280
- Optic neuropathy, paraneoplastic, 285
- Oral bioavailability, of taxanes for targeted cancer therapy, 427-428
- Organ transplantation, in cancer, neurotoxicity of  
infections transmitted by transplanted tissue, 357  
kidney transplantation, 359  
liver transplantation, 358-359  
post-transplantation lymphoproliferative disorder, lymphoma, and other secondary neoplasms, 357-358
- OS-9 protein, as endogenous HIF-1 inhibitor, 490-491
- Osteoporosis, menopausal, treatment among breast cancer survivors, 700-702
- Ovarian ablation and suppression, in premenopausal women with breast cancer, 658-659  
combined with chemotherapy, 659-660  
with tamoxifen, 660  
v chemotherapy, 659
- Oxaliplatin  
chemotherapy-related toxicity of  
renal toxicity, 70  
CIPN, clinical features of, 24-25  
calcium/magnesium infusions for, 42  
carbamazepine for, 41-42
- p27 cell cycle regulator, as prognostic marker of renal cell carcinoma, 572

- p53 tumor suppressor protein  
 as endogenous HIF-1 inhibitor, 490  
 as prognostic marker of renal cell carcinoma, 571
- Paclitaxel  
 in cancer chemotherapy, neurotoxicity of, 328  
 chemotherapy-related toxicity of  
 CIPN, clinical features of, 25-26  
   v docetaxel, 27-28  
 dermatologic toxicity, 86-89  
 nanoparticle albumin formulation of, see Abraxane
- Palmar-plantar erythrodysesthesia, chemotherapy-related, 128
- Pancytopenia, in bone marrow and stem cell transplantation, neurotoxicity during, 353-355
- Papillary renal cell carcinoma  
 hereditary, genetic basis of, 546-547  
 pathology of, 535-536
- Papillary thyroid cancer, *b-raf* mutations in, 396-397
- Paragangliomas, neurologic complications of, 350
- Paraneoplastic neurologic syndromes, 269  
 associated with leukemia and lymphoma, 344-345  
 cerebellar degeneration, 275-278  
   differential diagnosis, 277  
   pathogenesis, 277-278  
   treatment, 278  
 clinical findings, 270-271  
 cranial nerves  
   bilateral diffuse uveomelanocytic proliferation, 284-285  
   cancer-associated cone dysfunction, 284  
   melanoma-associated retinopathy, 284  
   optic neuropathy, 285  
   visual, 282-284  
 diagnosis, 271-273  
 encephalomyelitis  
   antibodies and, 280  
   autonomic neuropathy, 279-280  
   brainstem encephalitis, 279  
   cerebellar degeneration, 279  
   dorsal root ganglia, 279  
   hippocampus, 278-279  
   hypothalamus, 279  
   spinal cord, 279  
 incidence, 270  
 motor neuron disorders, 281-282  
 myelopathies  
   myelitis, 280  
   necrotizing, 280-281  
 myoclonus, 280  
 neuromuscular junction  
   cachectic myopathy, 292  
   inflammatory myopathies, 291-292  
   Lambert-Eaton myasthenic syndrome, 288-289  
   myasthenia gravis, 289-291  
   necrotizing myopathy, 292  
   neuromyotonia, 291  
 opsoclonus, 280  
 pathogenesis, 273-274  
 pathology, 274  
 peripheral neuropathy, 285-288  
   associated with plasma cell dyscrasia, 287-288  
   autonomic, 286-287  
   brachial, 288  
   Guillain-Barré syndrome, 288  
   motor, 286  
   sensorimotor, 286  
   sensory, 286  
   vasculitic, 288  
 prognosis, 274-275  
 Stiff-Person syndrome, 282  
 treatment, 275
- Paraneoplastic syndromes, in prognosis of renal cell carcinoma, 568
- Parapharyngeal tumors, neurologic complications of, 349-350
- PD-0325901, see Mitogen extracellular kinase inhibitors
- Pemetrexed, chemotherapy-related dermatologic toxicity of, 90-91
- Pentostatin  
 chemotherapy-related toxicity of  
   hepatotoxicity, 55  
   renal toxicity, 71-72  
 or fludarabine with cyclophosphamide, for fludarabine-refractory chronic lymphocytic leukemia, 212-213  
 relation to increased infection risk in chronic lymphocytic leukemia, 243-244
- Peptide antagonists, for Bcl-2 inhibition in targeted cancer therapy, 452
- Peptidomimetics, for targeted cancer therapy, 389-390
- Peripheral nerve, and nerve root, involvement in leukemia and lymphoma, 343
- Peripheral neuropathy  
 chemotherapy-induced  
   clinical challenges in diagnosis and quantification, 30  
   clinical diagnostic features, 20-21  
   clinical features associated with therapeutic agent  
   Abraxane, 27  
   bortezomib, 29  
   carboplatin, 24, 27-28  
   cisplatin, 24, 27-28  
   Cremophor EL, 26-27  
   cytarabine, 29-30  
   docetaxel, 27-28  
   etoposide, 29-30  
   interferon alfa, 29-30  
   oxaliplatin, 24-25, 41-42  
   paclitaxel, 25-28  
   procarbazine, 29-30  
   thalidomide, 29  
   vinca alkaloids, 28-29  
   common and serious clinical problem, 23-24  
   design and endpoint considerations for clinical trials, 42-43  
   diagnostic classification, 21-23  
   evaluation methods for, selection, standardization, and reliability determination  
   patient-based methods, 36-39  
   physician-based methods, 33-36  
   quantitative sensory tests and electrophysiologic measurements in combination with neurologic evaluations, 31-33  
   pathogenesis and pathophysiology, 18-20  
   prevention and treatment  
   amifostine, 40-41  
   calcium/magnesium infusions, 42  
   carbamazepine, 41-42  
   gabapentin, 41  
   glutamate, 41  
   glutamine, 41  
   glutathione, 41  
   nerve growth factor and analogs, 39-40  
   Tavocept, 42  
 paraneoplastic, 285-288  
   associated with plasma cell dyscrasia  
   cryoglobulinemia, 288  
   myeloma, 287  
   Waldenström macroglobulinemia, 287-288  
   autonomic, 286-287  
   brachial, 288  
   Guillain-Barré syndrome, 288  
   motor, 286  
   sensorimotor, 286  
   sensory, 286  
   vasculitic, 288  
 Pertuzumab, for targeted cancer therapy, 389



- Phagocytic defects, association with infections in chronic lymphocytic leukemia, 241-242
- Phorbol 12-myristate 13-acetate, for targeted cancer therapy, 471
- Phosphatidyl inositol-3-kinase, in multitargeted cancer therapy, 367-368, 407-417
- inhibition by mTOR inhibitors, 413-414
- Phytoestrogens, for menopausal vasomotor symptoms in breast cancer survivors, 697-698
- PKC, *see* Protein kinase C
- Plant alkaloids, in cancer chemotherapy, neurotoxicity of
- docetaxel, 328
  - paclitaxel, 328
  - vinca alkaloids, 328-329
- Plasma cell dyscrasia, peripheral neuropathies associated with
- cryoglobulinemia, 288
  - myeloma, 287
  - Waldenström macroglobulinemia, 287-288
- Platelet-derived growth factor, as target of renal cell carcinoma therapy, 591
- Platinum agents, chemotherapy-related toxicity of
- CIPN, clinical features of
    - carboplatin, 24, 27-28
    - cisplatin, 24, 27-28
    - oxaliplatin, 24-25  - hepatotoxicity, 53
  - renal toxicity
    - carboplatin, 70
    - cisplatin, 69-70
    - oxaliplatin, 70
- Platinum-based alkylating agents, in cancer chemotherapy, neurotoxicity of, 324-326
- Pleural effusions, chemotherapy-related, 98
- Plk1, *see* Polo-like kinase 1
- Pneumonitis, inflammatory interstitial, chemotherapy-related, 98
- Polo-like kinase 1, as target for cancer therapy, 440-441
- Polyethylene glycol-coated liposomal doxorubicin, chemotherapy-related dermatologic toxicity of, 89-90
- Postmenopausal women, adjuvant therapy for breast cancer in
- aromatase inhibitors, 673
    - after 2 to years of tamoxifen, 674-676
    - clinical trials, 674
    - decision-making and future directions, 677-679
    - extended adjuvant setting, 676-677
    - side effect profiles, 677  - tamoxifen, 672-673
- Post-transplantation lymphoproliferative disorder, in organ transplant recipients, 357-358
- Pregnancy, subsequent, impact in premenopausal breast cancer patients, 664-669
- Premenopausal women, with breast cancer
- adjuvant hormonal therapy for
    - ovarian ablation and suppression, 658-660
    - recommendations from consensus meetings, 660
    - research directions, 660-662
    - tamoxifen, 657  - fertility preservation and impact of subsequent pregnancy, 664-669
- Procarbazine, chemotherapy-related toxicity of
- CIPN, clinical features of, 29-30
  - hepatotoxicity, 53
  - lung injury, 101-102
- Progestagens, for menopausal vasomotor symptoms in breast cancer survivors, 700
- Progesterone receptor, in breast cancer, 635-636
- as marker of sensitivity to neoadjuvant endocrine therapy, 653-654
- Progestins, chemotherapy-related hepatotoxicity of, 59
- Prolymphocytic leukemia
- B-cell
    - clinical features, 260
    - cytogenetics and pathogenesis, 260-261
    - differential diagnosis, 261  - Prolymphocytic leukemia (*Continued*)
    - immunophenotype, 260
    - morphology, 260
    - treatment and prognosis, 261  - T-cell
    - clinical presentation, 257
    - cytogenetic features and pathogenesis, 258-259
    - differential diagnosis, 259
    - immunophenotype, 258
    - morphology, 258
    - treatment and prognosis, 259-260
- Promoter hypermethylation, aberrant, *see* Aberrant promoter hypermethylation
- Prophylactic cranial irradiation, for brain metastases, 304
- Prostate cancer, hormesis in androgen therapy for, 708-709
- Protein kinase C, as target for cancer therapy, 367
- modulators, *see also* Anti-PKC agents
    - clinical trials, 473-474
    - combination with standard chemotherapy, 474
    - preclinical study, 470-473
    - in multitargeted therapy, 407-417
    - inhibition by small molecules, 414
    - role in apoptosis, 469-470
    - role in cancer cell invasion, 470
    - role in multi-drug resistance, 470
    - signal transduction and, 468-469
    - structure, function, and distribution, 467-468
- PTEN gene, as prognostic marker of renal cell carcinoma, 572
- PTK 787/ZK222584, for renal cell carcinoma, 602
- Pulmonary edema, chemotherapy-related, 98
- Pulmonary toxicity, chemotherapy-related, *see* Lung injury, chemotherapy-related
- Pulmonary veno-occlusive disease, chemotherapy-related, 121-122
- Purine analogues, for chronic lymphocytic leukemia, 203-204
- with alkylating agent, 205-206
  - management of autoimmunity after, 235-236
  - relation to increased infection risk, 242
- Radiation, and renal cell carcinoma, 531
- Radiation sensitizers, for brain metastases, 304
- Radical nephrectomy, for renal cell carcinoma, 557
- cost of care, 553-554
  - local control and cause-specific survival, 555
  - morbidity, 553
  - multifocality, 554-555
  - preservation of renal function, 553
  - quality of life, 553
  - risk of benign tumors, 554
  - tumor size, location, and histology, 555-556
- Radioimmunoconjugates, for neoplastic meningitis, 320
- Radioisotopes, for neoplastic meningitis, 320
- Radiosurgery, stereotactic, as alternative to resection for brain metastases, 301-302
- Radiotherapy
- adjuvant, for renal cell carcinoma, 577
  - cardiotoxicity of, 3
  - for metastatic epidural spinal cord compression, 310
  - for neoplastic meningitis, 318
  - resistance to, role of Raf-1, 398
  - synergy with anti-EGFR cancer therapy, 377-378
- Raf kinase isoforms, in cancer, 367, 392-406
- effects on cell survival, 393-394
  - inhibitors
    - 17AAG, 399
    - antisense oligonucleotides, 399
    - MEK inhibitors, 399
    - sorafenib tosylate, 399-403  - role in radio- and chemoresistance, 398

- Raf kinase isoforms, in cancer, 367, 392-406 (*Continued*)  
 tumor progression and  
 angiogenesis, 397-398  
 metastasis, 398  
 tumorigenesis and, 395-397
- Raynaud's phenomenon, chemotherapy-related, 124
- Recombinant erythropoietin, in cancer chemotherapy, neurotoxicity of, 330
- Relapsed chronic lymphocytic leukemia  
 drug development history, 210-211  
 drug-sensitive, treatment of, 211  
 fludarabine-refractory  
 alemtuzumab (Campath-1H), 212-213  
 alternative nucleoside analogs, 214  
 flavopiridol, 214-215  
 fludarabine, cyclophosphamide, and rituximab, 213-214  
 fludarabine or pentostatin with cyclophosphamide, 213  
 high-dose methylprednisolone, 214  
 lenalidomide, 215  
 new antibodies and biologic therapies, 216  
 rituximab, 214  
 small molecules in early clinical trials, 215-216
- Renal cell carcinoma, 525-526  
 adjuvant therapy for, 576-581  
 angiogenesis inhibitors, 580  
 chemotherapy, 577-578  
 defining population at risk, 576-577  
 disease spectrum, 576  
 hormonal therapy, 577  
 immunotherapy, 578  
 interferon alfa, 578  
 interleukin-2, 578-579  
 monoclonal antibodies, 579  
 oncopophage vaccine, 579  
 radiation therapy, 577  
 sorafenib, 579-580  
 sunitinib, 580  
 tumor vaccines, 579  
 WX-G250, 579
- angiogenesis inhibitors for  
 AG013736, 602  
 BAY 43-9006, 601-602  
 bevacizumab, 596-599  
 controversies, 603-604  
 GW786034, 602-603  
 PTK 787/ZK222584, 602  
 SU11248, 599-601  
 VEGF-trap, 599
- epidemiologic aspects of  
 analgesics and, 529-530  
 antihypertensive agents and, 529  
 cigarette smoking and, 529  
 demography, 527  
 dialysis and, 530-531  
 dietary factors, 530  
 hormonal and reproductive factors, 530  
 hypertension and, 529  
 kidney transplantation and, 530-531  
 obesity and, 529  
 occupation and, 530  
 radiation and, 531  
 risk factors, 527-529
- metastatic, *see* Metastatic renal cell carcinoma
- molecular pathways and targeted therapy for  
 c-MET, 592  
 combined therapy, 592-593  
 CXC cytokine receptor 4, 592  
 cyclin D1/cdk4, 591-592  
 epidermal growth factor receptor, 591  
 erythropoietin, 591
- Renal cell carcinoma, 525-526 (*Continued*)  
 hypoxia-inducible factor, 589-590  
 matrix metalloproteinases, 592  
 platelet-derived growth factor, 591  
 transforming growth factor alpha, 591  
 vascular endothelial growth factor, 590-591  
 von Hippel-Lindau disease, 588-590
- mTOR inhibitors for, 607-609  
 clinical development, 609-610  
 future clinical trial designs, 611-612  
 patient selection using molecular criteria, 610-611
- pathology of  
 chromophobe, 537-538  
 clear cell, 534-535  
 hereditary forms, 539-540  
 immunohistochemistry, 540  
 papillary, 535-536  
 translocation-associated, 536-537  
 unclassified, 539
- prognosis of, 563-573  
 anatomic factors, 563-566  
 clinical factors, 567-568  
 comprehensive integrated prediction models, 568-570  
 histologic factors, 566-567  
 molecular markers, 570-572
- sorafenib tosylate for, 401-403
- surgery for  
 adequacy of resection, 556-557  
 cost of care, 553-554  
 local control and cause-specific survival, 555  
 for metastatic carcinoma, 557-559  
 morbidity, 553  
 multifocality, 554-555  
 nephron-sparing surgery, 552-553  
 preservation of renal function, 553  
 quality of life, 553  
 radical nephrectomy, 557  
 risk of benign tumors, 554  
 tumor size, location, and histology, 555-556
- vaccines for, 614-622  
 antigenic peptides, 620  
 artificial antigen-presenting cells and, 621  
 dendritic cell vaccines, 618-619  
 embryonic stem cells and, 621  
 gene-modified tumor cell vaccines, 618  
 heat shock proteins, 619-620  
 immature myeloid cells and, 621-622  
 regulatory T cells and, 622  
 tumor cell-based vaccines, 615-618
- Renal collecting duct carcinoma, pathology of, 538-539
- Renal epithelial neoplasms, pathology of  
 collecting duct carcinoma, 538-539  
 hereditary forms, 539-540  
 immunohistochemistry, 540  
 medullary carcinoma, 538-539  
 oncocytoma, 538  
 renal cell carcinoma  
 chromophobe, 537-538  
 clear cell, 534-535  
 papillary, 535-536  
 translocation-associated, 536-537  
 unclassified, 539
- Renal medullary carcinoma, pathology of, 538-539
- Renal oncocytoma, pathology of, 538
- Renal toxicity, chemotherapy-related  
 alkylating agents, 70-71  
 antimetabolites, 71-72  
 evaluation of renal function, 68  
 other agents, 72

- Renal toxicity, chemotherapy-related (*Continued*)  
  platinum agents, 69-70  
  risk factors, 68-69
- Reproduction, and renal cell carcinoma, 530
- Resection, for brain metastases  
  stereotactic radiosurgery as alternative to, 301-302  
  whole brain radiation therapy and, 300-301
- Residual chronic lymphocytic leukemia, frontline therapy for, 207
- Retinal-vessel toxicity, chemotherapy-related, 128
- Retinopathy, melanoma-associated, 284
- Richter's syndrome, in chronic lymphocytic leukemia  
  diagnostic evaluation, 252-253  
  etiologic and oncogenesis  
    chromosome 11q abnormalities, 251  
    EBV, 251-252  
    microsatellite instability, 251  
    trisomy 12, 251  
    tumor-suppressor genes, 251  
  incidence, 252  
  prognostic factors, 253  
  symptoms and signs, 252  
  treatment, 253-254
- Risk stratification, in chronic lymphocytic leukemia  
  clinical staging systems, 186  
  evaluation of autologous and allogeneic stem cell transplantation, 192-193  
  prognostic factors  
    genetic parameters, 187-191  
    markers of tumor burden, 186-187  
    serum parameters, 187  
  progression in early-stage chronic lymphocytic leukemia, 191-192  
  response to treatment and survival in advanced-stage chronic lymphocytic leukemia, 192
- Rituximab  
  for autoimmunity in chronic lymphocytic leukemia, 234-235  
  chemotherapy-related toxicity of  
    dermatologic toxicity, 91-92  
    lung injury, 102  
  for chronic lymphocytic leukemia, 204-205  
  and cyclophosphamide, and fludarabine, for fludarabine-refractory chronic lymphocytic leukemia, 213-214
- RNA aptamers, for targeted cancer therapy, 390
- RNAi gene silencing, in genome-wide identification of synthetic lethal targets, 517
- Salivary gland tumors, neurologic complications of, 349
- SART1/HAF, as endogenous HIF-1 inhibitor, 491
- sCD23, see Soluble CD23
- Securin, as target for cancer therapy, 441-442
- Seizures  
  in brain metastases, management of, 300  
  in brain tumors  
    AED interactions with chemotherapy and glucocorticoids, 339  
    choice, effectiveness, and adverse reactions of AEDs, 335-339  
    clinical features, 334  
    epidemiology, 333-334  
    prophylactic use of AEDs, 334-335  
    surgical management, 339-340
- Sensorimotor neuropathy, paraneoplastic, 286
- Sensory neuropathy, paraneoplastic, 286
- Separase, as target for cancer therapy, 441-442
- Skeletal muscle, involvement in leukemia and lymphoma, 343
- Smac/DIABLO, as prognostic marker of renal cell carcinoma, 572
- Small molecule kinase inhibitors, see Sorafenib; Sunitinib
- Small molecules  
  for fludarabine-refractory chronic lymphocytic leukemia, 213-216  
  for multitargeted cancer therapy, 414
- Small molecule-targeted therapeutic agents, causing chemotherapy-related lung injury, 102-103
- Solid organ transplantation, see Organ transplantation
- Solid tumors, in vivo, and Raf-1 overactivation, 395-396
- Soluble CD23, serum level as prognostic marker in chronic lymphocytic leukemia, 187
- Sorafenib  
  for renal cell carcinoma, 601-602  
    adjuvant therapy, 579-580  
  for targeted cancer therapy  
    melanoma, 400-401  
    multitargeted therapy, 415  
    renal cell carcinoma, 401-403
- Spinal cord, paraneoplastic encephalomyelitis, 279
- Spinal cord compression, epidural  
  due to leukemia and lymphoma, 343  
  metastatic, management of  
    historical review, 307-308  
    radiotherapy, 310  
    randomized trials, 308-309  
    surgery, 309-310  
    time to motor weakness as prognostic variable, 308
- Splenectomy, for autoimmunity in chronic lymphocytic leukemia, 234
- Staurosporine derivatives, for targeted cancer therapy, 472
- Stem cell transplantation  
  in cancer, neurotoxicity of, 352-357  
    after marrow reconstitution, 355-356  
    chronic graft-versus-host disease and, 357  
    during conditioning, 353  
    long-term immunosuppression and, 356-357  
    during pancytopenia, 353-355  
    during stem cell harvesting, 353  
  in chronic lymphocytic leukemia  
    autologous and allogeneic, risk evaluation of, 192-193  
    and graft-versus-leukemia effect, 226
- Stereotactic radiosurgery, as alternative to resection for brain metastases, 301-302
- Stiff-Person syndrome, paraneoplastic, 282
- Stromal cells, biologic implications in chronic lymphocytic leukemia, 178-179
- SU11248, see Sunitinib; Sunitinib malate
- Sunitinib, for renal cell carcinoma, 599-601  
  adjuvant therapy, 580
- Sunitinib malate, for multitargeted cancer therapy, 415-417
- Supportive care agents, chemotherapy-related hepatotoxicity of, 60
- Survivin, as target for cancer therapy, 367  
  apoptosis and, 479-480  
  cell division and, 480  
  expression in cancer, 480  
  inhibition by M<sub>4</sub>N, 481-482  
  inhibition in normal cells, 480-481  
  M<sub>4</sub>N in cell death independent of, 482-483
- Systemic chemotherapy, for neoplastic meningitis, 320-321
- T cells  
  regulatory, in reversal of tumor-mediated immunosuppression in renal cell carcinoma, 622  
  role in pathogenesis of autoimmunity in chronic lymphocytic leukemia, 233
- Tamoxifen  
  adjuvant, for postmenopausal women with breast cancer, 672-673  
    aromatase inhibitors after 2 to 3 years, 674-676  
  in cancer chemotherapy, neurotoxicity of, 329  
  in chemoprevention for breast cancer in high-risk women, 642-643  
    benign lesions and genetic predisposition, 643-644  
    guidelines, 644-645  
    ongoing studies, 645  
    patient monitoring, 645  
  for ductal carcinoma-in-situ, 647-649  
  neoadjuvant, for locally advanced breast cancer, 650-651

- Tamoxifen (*Continued*)  
 with ovarian ablation and suppression, in premenopausal women with breast cancer, 660
- Targeted cancer therapies, *see* Cancer, targeted therapies for
- Target-specific antineoplastic agents, chemotherapy-related hepatotoxicity of, 57-58
- Tavocept, for prevention and treatment of CIPN, 42
- Taxanes  
 chemotherapy-related toxicity of  
   cardiotoxicity, 7-8  
   CIPN, clinical features of, 25-27  
   dermatologic toxicity, 86-89  
   hepatotoxicity, 56-57  
   lung injury, 102  
 for management of chemotherapy extravasation, 142  
 for targeted cancer therapy, 422-423  
   advantages, 423-424  
   delivery systems, 424-428  
     abraxane, 424-425  
     CT-2103, 425-426  
     DHA-paclitaxel, 426-427  
     emulsions, 427  
     oral bioavailability, 427-428
- T-cell prolymphocytic leukemia  
 clinical presentation, 257  
 cytogenetic features and pathogenesis, 258-259  
 differential diagnosis, 259  
 immunophenotype, 258  
 morphology, 258  
 treatment and prognosis, 259-260
- tetra-O-methyl nordihydroguareic acid  
 as global transcription inhibitor in cancer, 483-484  
 survivin inhibition by, 481-482  
 in survivin-independent cell death, 482-483
- Thalidomide  
 in cancer chemotherapy, neurotoxicity of, 329  
 chemotherapy-related toxicity of  
   CIPN, clinical features of, 29  
   dermatologic toxicity, 91  
   hepatotoxicity, 58
- 6-Thioguanine, chemotherapy-related hepatotoxicity of, 54
- Thrombocytopenia, chemotherapy-related, 82-83  
 growth factor therapy, 83
- Thrombocytosis, in prognosis of renal cell carcinoma, 568
- Thrombosis, and thromboembolic complications, chemotherapy-related, 126-127
- Thrombotic microangiopathic syndrome, chemotherapy-related, 125-126
- Thymidine kinase, serum level as prognostic marker in chronic lymphocytic leukemia, 187
- Thyroid cancer, papillary, *b-raf* mutations in, 396-397
- TK, *see* Thymidine kinase
- TKIs, *see* Tyrosine kinase inhibitors
- TMPPy4, for c-MYC oncogene inhibition via G-quadruplex silencer element, 368, 498-510  
 in vivo activity, 509-510
- Topoisomerase inhibitors, chemotherapy-related toxicity of  
 dermatologic toxicity, 91  
 hepatotoxicity, 57
- Topotecan, chemotherapy-related toxicity of  
 dermatologic toxicity, 91  
 hepatotoxicity, 57
- Transforming growth factor alpha, as target of renal cell carcinoma therapy, 591
- Translocation-associated renal cell carcinoma, pathology of, 536-537
- Trastuzumab  
 chemotherapy-related toxicity of  
   cardiotoxicity, 8-10  
   dermatologic toxicity, 91-92  
 for targeted cancer therapy, 388-389
- Trioma cells, in vaccine development for chronic lymphocytic leukemia, 224
- Trisomy 12, in Richter's syndrome in chronic lymphocytic leukemia, 251
- Troponins, in monitoring of anthracycline cardiotoxicity, 7
- Tubulin, and mitosis, 436-437
- Tubulin-associated proteins, as targets for cancer therapy, 367  
 Aurora kinases, 431  
   Aurora A, 437-439  
   Aurora B, 439-440  
 mitotic kinesins, 430-431  
   KSP, 442  
   other potential targets, 442-443  
 Plk1, 440-441  
 securin, 441-442  
 separase, 441-442  
 unknown  
   chemical genetics, 443  
   genomic instability, 443-445
- Tubulin-polymerizing agents, for targeted cancer therapy, *see also* Anti-microtubule agents  
 discodermolide, 430  
 epothilones, 428-430
- Tumor antigens, in vaccine development for chronic lymphocytic leukemia, 222-223
- Tumor burden, in chronic lymphocytic leukemia, markers of, 186-187
- Tumor cells, producing autoantibodies in chronic lymphocytic leukemia, 231-232
- Tumor metastasis, and Raf kinase isoforms, 398
- Tumor necrosis, in prognosis of renal cell carcinoma, 567
- Tumor progression, and Raf kinase isoforms  
 angiogenesis, 397-398  
 metastasis, 398
- Tumor vaccines, for renal cell carcinoma, 614-622  
 adjuvant therapy, 579  
 antigenic peptides, 620  
 artificial antigen-presenting cells and, 621  
 cell-based vaccines, 615-618  
 dendritic cell vaccines, 618-619  
 embryonic stem cells and, 621  
 gene-modified tumor cell vaccines, 618  
 heat shock proteins, 619-620  
 immature myeloid cells and, 621-622  
 regulatory T cells and, 622
- Tumorigenesis, and Raf kinase isoforms  
 hormone-dependent cancer, 396  
 malignant transformation in vitro, 395  
 melanoma, 396  
 papillary thyroid cancer, 396-397  
 solid tumors in vivo, 395-396
- Tumor-suppressor genes  
 loss-of-function mutation as targets for anti-cancer drug development, 368  
   chemical genomics, 516-517  
   RNAi gene silencing, 517  
   synthetic lethality, 514-516  
 in Richter's syndrome in chronic lymphocytic leukemia, 251
- Tyrosine kinase inhibitors, for multitargeted cancer therapy, 367-368  
 investigational agents  
   mTOR inhibitors, 413-414  
   small molecules, 414  
   sorafenib tosylate, 415  
   sunitinib malate, 415-417  
   rationale, 409-411  
   strategies, 411-412
- Urogenital atrophy, menopausal, treatment among breast cancer survivors, 702-703
- Vaccination, for infection prevention in chronic lymphocytic leukemia, 246

- Vaccine development, for chronic lymphocytic leukemia  
altered tumor as antigen source, 223  
dendritic cells, 223-224  
gene therapy, 224  
idiotype, 222  
other tumor antigens, 222-223  
trioma cells, 224
- Vaccines, for renal cell carcinoma, *see* Tumor vaccines, for renal cell carcinoma
- Variable segment of immunoglobulin heavy chain genes, mutation status as  
prognostic marker in chronic lymphocytic leukemia  
global and targeted gene expression analyses, 190-191  
relation to genomic aberrations, 188-189  
surrogate markers, 189-190
- Vascular diseases, due to lymphoma and leukemia, 343-344
- Vascular endothelial growth factor  
in chronic lymphocytic leukemia  
autocrine pathway of, 177-178  
biologic implications, 178-179  
in renal cell carcinoma  
inhibitors of, *see* Angiogenesis inhibitors  
as target of therapy, 590-591
- Vascular toxicity, chemotherapy-related  
Budd-Chiari syndrome, 124  
capillary-leak syndrome, 128  
hepatic veno-occlusive disease, 122-124  
hypotension and hypertension, 127  
leukocytoclastic vasculitis, 128  
myocardial ischemia and infarction, 124-125  
palmar-plantar erythrodysesthesia, 128  
pathogenesis, 128-129  
pulmonary veno-occlusive disease, 121-122  
Raynaud's phenomenon, 124  
retinal-vessel toxicity, 128  
thrombosis and thromboembolic complications, 126-127  
thrombotic microangiopathic syndrome, 125-126
- Vasculitic neuropathy, paraneoplastic, 288
- Vasomotor symptoms, menopausal, treatment among breast cancer survivors  
antidepressants, 699
- Vasomotor symptoms, menopausal, treatment among breast cancer survivors (Continued)  
black cohosh, 698-699  
clonidine, 699  
gabapentin, 699-700  
phytoestrogens, 697-698  
progestagens, 700  
vitamin E succinate, 698
- VEGF, *see* Vascular endothelial growth factor
- VEGF-trap, for renal cell carcinoma, 599
- Venous system, and prognosis of renal cell carcinoma, 564-565
- V<sub>H</sub> genes, *see* Variable segment of immunoglobulin heavy chain genes
- Vinca alkaloids  
in cancer chemotherapy, neurotoxicity of, 328-329  
chemotherapy-related toxicity of  
CIPN, clinical features of, 28-29  
dermatologic toxicity, 91  
hepatotoxicity, 56  
lung injury, 102  
for management of chemotherapy extravasation, 142
- Vincristine, chemotherapy-related renal toxicity of, 72
- Vinorelbine, chemotherapy-related dermatologic toxicity of, 91
- Visual disorders, paraneoplastic, 282-284  
bilateral diffuse uveomelanocytic proliferation, 284-285  
cancer-associated cone dysfunction, 284  
melanoma-associated retinopathy, 284  
optic neuropathy, 285
- Vitamin E succinate, for menopausal vasomotor symptoms in breast cancer survivors, 698
- von Hippel-Lindau disease  
genetic basis of, 544-546  
molecular pathways, 588-590  
mTOR and, 608-609  
tumor suppressor protein, 571
- Waldenström macroglobulinemia, peripheral neuropathies associated with, 287-288
- Whole brain radiation therapy, for brain metastases, 300, 302-303  
resection and, 300-301
- WX-G250, in adjuvant therapy for renal cell carcinoma, 579